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CH.&.fT~:B_I 
GENERAL INTRODUCTION 
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Cancer immunotherapy may be defined as the use or modifi-
cation of elements of the immune system to limit or eliminate 
neoplastic growth. This has been an appealing concept since 
Ehrlich in 1900 postulated the presence of differences between 
surface membrane antigens of normal and tumor cells allowing an 
immunocompetent organism to recognize and destroy abnormal cells. 
The existence of tumor restricted immunity was first shown by 
Gross (1943) who found resistance against tumorogenic doses of a 
chemically induced sarcoma if mice were sensitized first with a 
small number of the same tumor cells. These findings were 
confirmed later by Foley (1953). Using inbred mice, Prehn and 
Main (1957) and Klein et al. (1960) demonstrated the specific 
resistance against rechallenge with a previously excised, methyl-
cholanthrene-induced tumor. The tumor was accepted by syngeneic 
mice not previously exposed to the tumor. 
Interest arose which effector mechanism dominated tumor 
rejection. Mitchison showed in 1954 by transfer experiments the 
ability of presensitized lymphocytes, obtained from draining 
lymph nodes of non-susceptible tumor-bearing mice, to accelerate 
tumor graft rejection in other mice, whereas serum alone failed 
to do so. Gorer and Amos (1956), however, were able to 
demonstrate protection against an inoculum of tumor cells 
by passive immunization with hyperimmune serum. 
Further exploration of the immune system led to delineation 
of the immune system into cellular (T cell) and humoral (B cell) 
components (Cooper et al., 1966; rev. Roitt et al., 1969). Mean-
while Burnet formulated his famous immunosurveillance theory 
(Burnet, rev. 1971) based on the postulation that tumor-specific 
or tumor-associated antigens exist, distinct from the non-trans-
formed cells from which they arose and that an immune response 
may occur against these antigens. After this period tumor immuno-
logy underwent an acceleration especially by the development of 
the hybridoma technology (Kphler and Milstein, 1975) and by the 
introduction of new techniques in molecular biology (rev. Wein-
berg, 1985). New areas of the immune system were revealed and 
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tumor surveillance appeared not anymore exclusively a T cell 
restricted phenomenon, but the involvement of humoral antibodies, 
macrophages and natural killer cells has been documented as well 
(rev. Wheelock and Robinson, 1983; rev. Den Otter, 1986). 
As regards the concept of tumor-specific antigens, which are 
supposed to play a key role in many therapeutical approaches, 
much scepticism has raised about their very existence and immuno-
genicity, except for virally, chemically or physically induced 
experimental tumors (rev. Weiss, 1980). Therefore, a more accu-
rate term might presently be: tumor-associated antigens. In view 
of the heterogeneity of these antigens the definition remains 
also difficult, but may be at best formulated as "a molecule 
which presence renders the cancer cell quantitatively or qualita-
tively different from its normal counterpart" (Sulitzeanu, 1985). 
The use of immunogenic tumors in animals as a model for human 
immunotherapy has been the subject of debate (Hewitt, 1982; 
Herberman, 1983). It seems however reasonable to assume that 
unsuccessful therapy in such models precludes its clinical use 
(rev. Ross and Steele, 1984). 
The development of tumor immunology has greatly inspired the 
use of new immunotherapeutical methods. However, the clinical 
applications reported are far from conclusive (rev. Oldham, 1983; 
rev. Rosenberg, 1984; rev. Reisfeld and Cheresh, 1985), 
sporadically showing promising results (Miller et al., 1982; 
Rosenberg et al., 1985). It is obvious that much more 
experimental work has to be done before different forms of 
immunotherapy find their place between the traditional modalities 
as surgery, radiotherapy and chemotherapy. 
This thesis deals with one variant of immunotherapy, namely 
the use of tumor-specific antibodies to induce tumor destruction. 
The experimental work falls apart into four succeeding phases: 
a) definition of the model, which means the choice of the animal 
and the tumor, the generation and characterization of the 
monoclonal antibodies; b) testing the monoclonal antibodies for 
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their ability to find the right target io_YiYOi c) testing these 
antibodies on the suitability for immunotherapeutical purposes; 
d) investigations on the underlying mechanism which may lead to 
tumor cell destruction. 
An artificial tumor metastasis model was chosen to imitate in 
a controlled way metastatic cancer, which is still the major 
problem in conventional therapy of malignant neoplasias. 
The non-producing Rauscher virus induced myeloid leukemic 
cell line RMB-1 was selected (De Both et al., 1981). Experiments 
carried out in 
Chapters II - VI. 
the order as outlined above are reported in the 
Chapter II deals with the characterization of 
two monoclonal antibodies directed against the viral protein p12, 
its precursors and a glycosylated polyprotein. In Chapter III 
results on specific io_yiyg targeting of both monoclonal 
antibodies are reported and discussed. Chapter IV deals with the 
use of one monoclonal antibody for immunotherapy in a 
disseminated tumor model; its possibilities and limits are 
investigated. In Chapter V an attempt is made to explore the 
underlying mechanism by carrying out io vivo and io vitro 
experiments and by histological studies. Chapter VI is directed 
to one aspect of the underlying mechanism, namely delayed-type 
hypersensitivity elicited by the tumor cells in the 
immunocompetent host. In Chapter VII the model is discussed in 
the context of the contemporary literature. 
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3.1 General outline 
The RNA tumor viruses (oncovirinae) are a subfamily of the 
retroviruses (retroviridae). The former were among the first 
agents that were discovered to cause tumors in animals. 
Initially the transmission of chicken erythroleukemias and 
sarcomas by cell free extracts was described by Ellerman and Bang 
(1908) and by Rous (1910), but it took 40 years to demonstrate 
this for murine leukemias in 1951 by Gross (rev. Gross, 1970). 
Since that time many other leukemia inducing murine retroviruses 
have been described, some of which cause myeloid and erythroid 
leukemias as the Graffi, Friend and Rauscher virus (rev. Gross, 
1970). RNA tumor viruses have also been found in many other 
vertebrates e.g. birds, other rodents, cats and monkeys (rev. 
Stephenson et al., 1978; rev. Weiss et al., 1982). During the 
past years also human retroviruses are isolated, which induce 
(T cell) leukemias (HTLV I, II) and the acquired immune 
deficiency syndrome (HIV) (rev. Wong-Staal and Gallo, 1985; rev. 
Weiss, 1987). 
3.2 Murine leukemia viruses 
Murine leukemia viruses (MuLV) belong to the C-type RNA tumor 
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viruses and measure about 1000 A in diameter. They are composed 
of an envelope covering the centrally located viral core 
(Fig. 1). The envelope consists of a lipid bilayer from which 
knobs project consisting of the major envelope glycoprotein gp70, 
loosely connected to the surface by the transmembrane envelope 
protein p15E. Between these stalks the protein p12E is present 
(rev. Bolognesi et al., 1978). The internal viral structure is 
constituted by four proteins of p15, p12, p30 and p10. The 
opinions about the composition of the inner coat between envelope 
and core are controversial. Some authors suggest that p15 is 
present in the inner coat (Barbacid and Aaronson, 1978; 
Vander Ven et al., 1978), whereas others assume that p15 is 
located just exterior to the core (rev. Bolognesi et al., 1978). 
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Fig. 1. Type C virus particle (modified toW. Hesselink). 
The principal constituent of the core shell is p30. P10 forms a 
ribonucleoprotein complex with the viral RNA, which consists of 
two identical 35S molecules linked together by hydrogen bonds. 
P12, which is a phosphoprotein with the property to bind 
specifically to the homologous genomic RNA (Sen and Todaro, 
1976), is most probably located in the core. The morphological 
aspects and the composition of type C RNA viruses are reviewed by 
Montelaro and Bolognesi (1978). 
3.3 The viral genome 
The RNA genome of retroviruses consists of three regions 
called g?g, pg~ and ~oy, which encode respectively for viral core 
proteins, the enzyme reverse transcriptase and the envelope 
glycoprotein, respectively. On the 5'- and 3'-sites repeats are 
present called RU5 and RU3. The viral RNA has a structure, which 
is homologous to that of messenger RNA having a cap site on the 
5'-end and a poly-adenosine tail on the 3'-end. 
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3.4 Viral replication 
After adsorption of the virion to cellular receptors the 
virus is endocytosed and the particle dismantled. The viral RNA 
comes free in the cytoplasm. By means of reverse transcriptase, a 
RNA-dependent DNA polymerase, present in the virus particle, a 
DNA copy is formed, which is complementary to the viral RNA. 
After degradation of the RNA, the DNA is duplicated and transpor-
ted to the cell nucleus. The linear DNA is circularized by DNA 
ligase into two circular forms of which only one is integrated as 
provirus into the cellular DNA. In this manner genetic informa-
tion is added to the genome of the infected cell and if such 
cells divide, transmitted to the daughter cells. In general the 
integration is at random. 
3.5 Provirus 
The structure of the proviral genome differs from the viral 
genome in that at both sites a long terminal repeat is present, 
called LTR, which consists of U5, R and U3. 
The LTR contains enhancer and promoter elements by which 
viral RNA synthesis can be induced. The unspliced RNA of 35S is 
incorporated into the virion, whereas spliced RNA is translated 
into viral proteins. 
3.6 Virally encoded protein synthesis 
The ~ region of the virus codes for a 65 kDa precursor 
protein, which is cleaved via intermediates into the core pro-
teins p15, p12, p30 and p10 (Fig. 2). 
The gag proteins are also expressed on the membranes of virus 
infected cells as part of a glycosylated polyprotein. The pgl 
region encodes for reverse transcriptase p75, a smaller protein 
of 14 kDa which is responsible for proteolytic cleavage of the 
precursor Pr200gag-pol and an enzyme called integrase (p46), 
which is involved in proviral integration. 
The envelope glycoprotein gp70 and the transmembrane protein 
p15E are formed from a precursor gPr80env. The p15E is partly 
cleaved into p12E. The viral envelope glycoproteins migrate to 
the cell membrane and are inserted in the cell surface. Subse-
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Fig. 2. Rauscher proviral genome and processing of its precursor proteins. 
quently, the viral core proteins, reverse transcriptase and the 
genomic RNA are transported to this site. 
After assembly and packaging the viral particle leaves the 
cell by budding. Since in the same cells multiple integrations 
can take place and since one provirus 
synthesis of many virus particles, the 
amplified in infected animals. 
can give rise to the 
virus is strongly 
The viral replication and protein processing are reviewed by 
Goff and Lobel (1987). 
3.7 Viral host range 
The host range of MuLV is mainly determined by the properties 
of the viral envelope glycoprotein gp70, which interacts with the 
cellular receptor (DeLarco and Todaro, 1976; Cloyd et al., 1985). 
According to their host range four virus classes are known: 
ecotropic only infectious for murine cells; 
xenotropic only infectious for non-murine cells; 
amphotropic: infectious for murine and non-murine cells; 
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dual tropic mink cell focus-inducing (MCF): identical in host 
range to amphotropic viruses, 
from the latter serologically 
but are distinguished 
and by their ability 
to induce cytopathological changes in mink lung 
cells (Hartley et al., 1977). 
MCF viruses are recombinants derived by substitution of a 
part of the ecotropic sequences by endogenous xenotropic-like 
sequences in the viral euy gene region (Chattopadhyay et al., 
1981; rev. Famulari, 1983; Fischinger et al., 1985). Recently 
another class of recombinant viruses has been reported which are 
antigenically and structurally similar to MCF viruses, but have 
an ecotropic host range (Cloyd and Chattopadhyay, 1986). Their 
pathogenicity is uncertain. 
Another classification is made on the basis of susceptibility 
of mouse strains to various viruses. Two classes are discerned: 
N- (NIH/Swiss cells) and B- (BALB/c cells) tropic viruses. This 
tropism is determined by the presence of the fy-1n/n or fy-1b/b 
genotype (Hartley et al., 1970). fy-1n/b mice are resistent to 
both N- and B-tropic viruses (rev. Meruelo and Bach, 1983). 
3.8 Viral strains 
Retrovirus strains which induce leukemias can be divided into 
~gyt~ and cbrogig viruses. The former group includes the Friend 
and Rauscher virus, induces an acute erythroid leukemia and kill 
the infected mice within 4 weeks. Chrogic viruses as the Gross, 
AKR and Moloney leukemia virus act more slowly and are lethal 
after more than half a year. 
The agyt~ leukemia viruses consist of a replication defective 
component and a replication competent virus which functions as a 
helper virus and complements the defective parts of the former. 
The avian defective leukemia viruses contain an oncogene (see 
further on) and in mice the defective virus has recombined with 
endogenous xenotropic viral sequences particularly in the region 
of the ~UY gene. 
In Rauscher virus the defective component is called Spleen 
Focus Forming Virus (R-SFFV), whereas the helper virus is denomi-
nated as R-MuLV. The helper virus can be purified separately (Mol 
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et al., 
(Reddy 
myeloid 
sarcoma 
1982) and induces chronic B cell or T cell leukemias 
et al., 1980; de Both et al., 1983) and occasionally 
leukemias (de Both et al., 1981, 1985). The murine 
virus, which is often used in immunotherapy studies, is a 
recombinant of the Moloney leukemia virus with the ~ oncogene 
and induces rhabdomyosarcomas (Papkoff et al., 1982). 
The Rauscher, Friend and Moloney viruses show homology both 
in nucleotide sequences and in serology and are often referred to 
as the FMR group. THe AKR and Gross viruses are also mutually 
related (rev. Old and Stockert, 1977). 
3.9 Leukemogenesis 
The agyte leukemia viruses cause a rapidly progressive 
leukemia by the direct mitogenic or transforming action of the 
defective viral component, which has undergone recombination with 
cellular sequences. The proliferation of specific leukemic target 
cells becomes disregulated by the direct action of the virus. It 
is assumed, that the virus (or viral proteins) interacts with 
specific receptors of growth factors or mimic these growth 
factors. In the case of acute Rauscher virus induced 
erythroleukemias (Rauscher, 1962), factors involved in erythroid 
differentiation would interact with retroviral proteins, 
especially with the eoy encoded deleted glycoprotein gp 55 (Ruta 
et al., 1983; Ruscetti and Wolf, 1985). However, the leukemic 
blasts are still capable of differentiating in long-lived 
erythrocytes as in the polycythemia inducing variant of Friend 
virus (FVP) (Tambourin et al., 1973) or in short-lived 
erythrocytes resulting in anemia as in Rauscher leukemia (de Both 
et al., 1980). 
In cb~ooic leukemias the leukemogenesis is 
stood. Chronic leukemia viruses ar~ sometimes 
uninfected animals as endogenous viruses 
activated with age. In other strains newborn 
less well under-
already present in 
which may become 
mice have to be 
infected to prevent immunological rejection of the virus and to 
induce leukemia. Different hypotheses exist how these viruses 
which do not carry themselves an oncogene or dualtropic viruses 
induce leukemia. 
14 
~~ Generation of Mink Cell Focus Forming (MCF) viruses 
Some authors assume that ecotropic viruses have to recombine 
with xenotropic virus sequences to form dualtropic viruses which 
can also infect non-rodent cells (Hartley et al., 1977; rev. 
Famulari, 1983; Fischinger et al., 1985). These dualtropic 
viruses are thus able to bind to different receptors than the 
original ecotropic virus, resulting in additional infections. 
MCF viruses can be isolated from many murine lymphomas and 
leukemias. When mice are infected with this type of virus, 
leukemias can be induced, but only after a long latent period 
(van Griensven and Vogt, 1980; Zijlstra et al., 1984). It is not 
precisely known how these viruses cause leukemia, but it may be 
that infection with these viruses results in a second hit as part 
of a multistep mechanism, which leads to leukemogenesis. Other-
wise the altered envelope glycoproteins may be involved in the 
induction or maintainance of the leukemic state (rev. Neil and 
Forrest, 1987). 
g~ Insertional mutagenesis 
Although proviral integration is at random, it is found in 
avian and murine lymphomas, that proviruses may activate cellular 
genes, especially proto-oncogenes which are the cellular equiva-
lents of oncogenes present in many transforming retroviruses. 
Generally these proto-oncogenes represent loci which products 
transduce signals involved in the regulation of cell prolifer-
ation. At present, more than 20 of such proto-oncogenes are 
known. 
It is assumed that sequences 
repeat (LTR) of ecotropic as well 
of the viral long terminal 
as MCF viruses promote or 
enhance the expression of proto-oncogenes lying in the vicinity 
of the integrated provirus (Hayward et al., 1981; Corcoran et 
al., 1984). A number of important integration sites lying in a 
particular chromosomal region have been discovered. Since these 
sites do not represent genes which are present in transforming 
retroviruses, they are called putative oncogenes. 
One of the first detected was tut-1 in virally induced 
mammary carcinomas (Nusse and Varmus, 1982). In murine lymphomas 
induced by AKR and Moloney virus QiiD-1 is described (Cuypers et 
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al., 1986). Recently also in Friend helper virus induced lympho-
mas and in myeloid leukemias specific integration sites are 
detected called fi~-1 (Silver and Kozak, 1986) and fi~-1 and -2 
(Sola et al., 1986). However, in all these cases the integration 
sites reported are only detected in part of the leukemias. As 
these reported integration sites do not seem obligatory, 
activation of other oncogenes may also trigger leukemogenesis. 
~ Induction of rearrangements and amplification of oncogenes 
In a number of virally induced plasmacytomas a translocation 
is reported between chromosome 15 and 12. By this 
oncogene on chromosome 15 is transferred to a 
enhancers and promoters involved in immunoglobin 
on chromosome 12 (Stanton et al., 1983). Often 
transcripts are truncated. 
process the ~YQ 
site near to 
synthesis lying 
the oncogenic 
In the Rauscher virus induced myeloid cell line (RMB-1), 
which is used for our experiments, a trisomy of chromosome 15 is 
reported (Hageme~er et al., 1982), similarly as in lymphomas 
induced by Moloney leukemia virus (Spira et al., 1979). It is 
suggested, that these extra chromosomes impose a proliferative 
advantage to the cells, but it is not known how, and if, these 
extra chromosomes as such induce leukemogenesis (Klein, 1981). 
g. Other hypotheses 
Several other, sometimes more indirectly operating mechanisms 
are postulated. 
An interesting hypothesis has been proposed by McGrath et al. 
(1980). The concept is that T cells are induced to proliferate 
after binding of leukemia viruses to mitogenic receptors. The 
prediction that proliferation could be blocked by substances that 
interfere with virus-receptor interaction could be verified 
(McGrath et al., 1980). It has been suggested that chronic 
antigenic stimulation caused by viraemia, leads to continuous 
production of lymphokines as IL-2 and IL-3 by lymphocytes. This 
may in turn facilitate the generation of lymphomas (Ihle et al., 
1982), possibly by increasing the rate of mutations during 
extensive proliferation. 
Otherwise leukemogenesis may be privileged by immunosuppress-
ion. Viral derivatives as the envelope protein p15E may act as 
16 
immunosuppressive agents as suggested by in vit~Q studies (Mathes 
et al., 1978; rev. Bendinelli, 1985), creating an opportunity for 
neoplastic growth. 
3.10 Genetic influence of the host 
The degree of resistance to viraemia and to infected or 
transformed cells may determin~ the progress of leukemogenesis. 
The susceptibility to viraemia as well as the expression of viral 
proteins, needed for immune recognition, are under genetic 
influence of the host, sometimes closely associated with the 
murine major histocompatibility (H-2) complex (rev. Meruelo and 
Bach, 1983). Otherwise virus infection may be influenced by the 
fy-1 locus, which interacts with the integration of viral DNA 
(Jolicoeur and Baltimore, 1976; Jolicoeur and Rassart, 1981). The 
immune response to viraemia and cells expressing viral proteins 
is generally H-2 linked (Vlug et al., 1981, 1983). However it can 
be associated with non-H-2 genes as exemplified by the BfY-3 
gene, which influences the antibody level in mice infected with 
the Friend virus complex (Chesebro and Wehrly, 1979). 
3.11 Antigenicity of viral proteins 
By means of competitive radio-immuno assays (RIA) or virus 
neutralization studies the viral proteins have been shown to 
possess antigenic determinants, which can be divided into three 
groups, present in different proportions on each structural 
protein. 
a) Type specific determinants shared by viruses of the same 
strain. 
b) Group specific determinants shared by viruses of the same 
species. 
c) Interspecies specific determinants shared by viruses of 
different species. 
The distribution of the various determinants is presented in 
Table I. 
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Table I 
Viral protein Type Group Interspecies Reference 
gp 70 +++ ++ (+) 
p15E ++ ++ 
p12E ++ 
p30 (+) +++ ++ 
p15 (+) ++ ++ 
p12 +++ (+) 
p10 ++ ++ 
p75 ++ + 
Steeves and Strand, 1974; August et 
al., 1974; Lilly and Steeves, 1974; 
Hino et al., 1976; Ihle et al., 1976; 
Barbacid et al., 197f; Stephenson et 
al, 1978; Nowinski et al., 1978; 
Chesebro et al., 1981, 1983; Weiss et 
al., 1982; Gambke et al., 1984. 
Schafer et al., 1975; Ihle et al., 
1976; Stephenson et al., 1978; Nowinski 
et al., 1978; Chesebro et al., 1981, 
1983; Gambke et al., 1984. 
Nowinski et al., 1978, Gambke et al., 
1984. 
Lilly and Steeves, 1974; August et 
al., 1974; Stephenson et al., 1974, 
1978; Sherr et al., 1975; Strand and 
August, 1975; Stephenson et al., 1977; 
Weiss et al., 1982; Gambke et al., 
1984; Chuat et al., 1985. 
Strand et al., 1974; Barbacid et al., 
1976, 1977, 1978; Chesebro et al . , 
1981. 1983; Weiss et al., 1982. 
Stephenson et al., 1974, 1977, 1978; 
Lilly and Steeves, 1974; August et 
al., 1974; Barbacid et al., 1976, 
1977; Weiss et al., 1982; Gambke et 
al., 1984. 
Lilly and Steeves, 1974; August et 
al., 1974; Barbacid et al., 1976, 
1977; Stephenson et al., 1977, 1978; 
Weiss et al. 1982. 
Parks et al., 1972; Sherr et al., 
1975; Panet and Kra-Oz, 
1978; Weiss et al., 1982. 
3.12 MuLV-induced cell surface antigens 
A number of cell surface antigens is expressed on MuLV 
infected or transformed cells (rev. Bauer, 1974; rev. Old and 
Stockert, 1977; rev. Kurth et al., 1979). These proteins may be 
divided into viral envelope proteins, glycosylated ggg poly-
proteins and virus induced cellular proteins. The most well known 
and some recently reported antigens are presented in Table II. 
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Table II 
Antigen Tissue distribution 
G1X Gross MuLV induced leukemic 
cells, thymocytes of high 
leukemic (AKR, C58, C3H) and 
some low leukemia incidence 
strains (129, A) 
G(rada) Normal and leukemic lymphoid 
tissues of high leukemia 
incidence strains 
FMR Friend, Moloney, Rauscher 
virus infected cells. 
G(B10.A) B10.AV+ lymphoma cells, 
RADA1 tumor cells, spleen 
cells of young adult B10.AV+ 
and B10.AV-mice 
B6RV2 RadLV induced leukemic cells 
of C57BL/6 mice 
G(erld) Normal and leukemic lymphoid 
tissues of high leukemic 
incidence strains 
Associated 
viral protein 
References 
ecotropic gp70 Old et al., 1964b; 
Stockert et al., 1971; 
Old and Stockert, 1977. 
ecotropic gp70 Obata et al., 1978; 
Old and Stockert, 1977. 
ecotropic gp70. Old et al., 1964; Old 
and Stockert, 1977; 
Nowinski et al., 1978. 
(ecotropic) gp70 Vlug et al., 1983. 
(dual tropic) 
(ecotropic) gp70 Nakayama et al., 1984. 
xenotropic gp70 Old and Stockert, 1977; 
Obata et al., 1981. 
G(aksl2) AKR leukemic cells and thyme- dualtropic gp70 
cytes from young mice of high 
Old and Stockert, 1977; 
Stockert et al.,1979; 
Famulari, 1983. 
XenCSA 
MCSA 
P120 
X1 
leukemia incidence strain 
Lymphocytes of all inbred dualtropic gp70 
mouse strains (most expressed 
in high leukemia incidence 
(AKR, C58, PL) strains) 
Cells infected with repli- glycosylated 
eating Gross-MuLV gag-polyprotein 
Mo-MuLV induced lymphomas gag proteins 
env proteins 
Abelson MuLV transformed cells gag proteins 
Hemopoietic tissues of high 
leukemia incidence strains 
(AKR, C58, C3H) and BALB/c, 
A and AKR leukemias 
Morse et al., 1979. 
Old et al., 1964; Tung 
et al., 1976; Ledbetter 
and Nowinski, 1977. 
Karande et al., 1979; 
Hesseling et al., 1981. 
Witte et al., 1979. 
Sato et al., 1973; 
Old and Stockert, 1977. 
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PC-1 
TL 
ML 
PC-2 
gp175 
YE6/6 
BALB/c myeloma cells and liver, 
kidney, brain, lymph node and 
some spleen cells of a number 
of PC-1+ strains (C:5H, A, 
BALB/c, NZB/BL, AKR, etc.) 
Differentiation antigen which 
may appear on leukemic thymo-
cytes of TL- strains 
DBA/2 leukemic cells, mammary 
tissues and mammary tumors of 
mice infected with mammary tumor 
virus. 
Plasma cells and plasmacytomas 
of BALB/c origin 
Friend, Moloney, Rauscher 
virus infected cells. 
Chemically, virally (Mo-MuLV) 
induced or spontaneous arosen 
lymphomas and leukemic cells of 
AKR, BALB/c and DBA/2 origin. 
induced by AKR, Mo-MuLV or 
A-MuLV 
Old and Stockert, 1977; 
Takahushi et al., 1979. 
Old and Stockert, 1977. 
Stuck et al., 1974; 
Old and Stockert, 1977. 
Tada et al., 1980. 
Rogers et al., 1984. 
Takei, 1987. 
* Identical glycoproteins are described for Friend (Evans et al., 1977), 
Moloney (Edwards and Fan, 1979) and Rauscher virus infected cells 
(Schultz et al., 1979). 
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4.1 The H-2 complex 
It is well established that the immune response acts in the 
context of the major histocompatability complex (MHC), in the 
mouse called the H-2 complex. The H-2 complex of the mouse is 
localized on chromosome 17 and can be divided in a K, I, s, D, L, 
Qa and TLa region. The K, D and L regions encode for the class I 
MHC products, which control the recognition by the cytotoxic 
T lymphocytes (CTL), while the I region codes for the class II 
MHC molecules, which function as restriction elements for 
helper T cells (rev. Klein and Nagy, 1982; rev. Doherty et al., 
1984). 
Class I molecules ar found on cells of almost all tissues. 
The class I genes are highly polymorphic and more than 
100 alleles at H-2K and H-2D are known (Doherty et al., 1984). 
The function of the class I-like TLa and Qa regions is uncertain 
(rev. Klein and Nagy, 1982). 
Class II molecules are expressed mainly by B cells and macro-
phages and serve as focussing sites for helper T cells. The 
I region is further divided in an I-A and an I-E domain. 
Loci in the S-region encode for some serum proteins as C2, C4 
and factor B which are not restrictive for the immune responses. 
These products are often called Class III molecules. 
4.2 Humoral response 
It has been shown that against a number of tumors a natural 
resistance or immunological host response may occur, depending on 
the properties of the tumor and the host (rev. Wheelock and 
Robinson, 1983; rev. Meruelo and Bach, 1983; rev. Den Otter, 
1986). Both humoral and cellular immune responses may occur, 
which probably interact in a complicated manner, involving 
lymphokines and other mediator substances. To study the function 
of the various parts of the system, often tumors are employed 
which are highly immunogenic and which are often chemically, 
physically or virally induced. In these studies the role of 
antibodies has been explored in immunocompetent hosts, 
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correlating the antibody level to progression or regression of 
the tumor (Lamon et al., 1973; rev. Levy and Leclerc, 1977; Key 
and Haskill, 1981a; Ciavarra and Terres, 1984) and lu yltro by 
analyzing (hyper-)immune sera and measuring their effects on 
tumor and presumed effector cells (Lamon et al., 1976; Langlois 
et al., 1981; Kawashima et al., 1985). Also B cell deprived 
animals were screened for their susceptibility to tumor growth 
(Gordon et al., 1982). Otherwise the effect of the 
administration of immune sera on tumor growth and tumor 
prevention was studied (Gorer and Amos, 1956; Fefer, 1970; 
Haagenesen et al., 1981; Herlyn and Koprowski, 1982; Lamon et 
al., 1987). The latter subject will be discussed later. 
From all these studies it can be concluded that naturally 
occurring anti-tumor antibodies may act beneficially, exerting 
their effect mainly via an antibody dependent cellular 
cytotoxicity (Shin et al., 1975; Levy et al., 1979; Key and 
Haskill, 1981b). Sometimes, however, detrimental influences may 
be observed by the induction of blocking factors which presumably 
exist of antibody-antigen complexes. These immune complexes can 
act in an immunosuppressive way, thus enabling tumor growth 
(Hellstrom and Hellstrom, 1969, rev. 1974). 
4.3 T cell response 
The importance of a T cell mediated response in tumor graft 
rejection has been acknowledged since three decades (Mitchison, 
1954). The function of the several T lymphocyte subsets has been 
related to separate phenotypes (Cantor and Boyse, 1975a, 1975b; 
Beverley et al., 1976). Generally Lyt-1+ cells are associated 
with helper activity. By secretion of lymphokines these cells 
enhance the generation of CTL and cause activation of macropha-
ges. Lyt-2+3+ lymphocytes on the other hand, are precursors of 
CTL, and can mediate after activation cytotoxic activity. Also 
many suppressive activities are mediated by Lyt-2+3+ cells. 
These classifications are, however, not absolute (rev. Hamaoka 
and Fujiwara, 1987), partly because the Lyt-1 marker was found to 
occur on CTL as well. The L3T4 marker was found to correlate more 
exclusively with the helper T function. (Dialynas et al., 1983). 
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Mostly, highly immunogenic tumors have been used to study the 
involvement of T cell mediated rejection (rev. Levy and Leclerc, 
1977; rev. North, 1985). The involved T cell subpopulations were 
analysed by selective elimination of the various subsets with 
specific monoclonal antibodies and complement. Several 
approaches have been followed: a) In vitro mainly by testing 
killer activity of (presensitized) cytotoxic T lymphocytes 
(Lyt1-2+) using 51cr or 3H release of previously labelled cells 
(Lamon et al., 1972; Shiku, 1976); b) In vtvo by testing 
prevention of tumor growth, either by simultaneous injection of 
tumor and effector cells (Winn-type assay) (Shimizu and Shen, 
1979; Prat et al., 1983; Fuyama et al., 1985) or by induction of 
regression of an established tumor by adoptive transfer of 
immmune splenocytes (Fernandez-Cruz et al., 1980; Rosenberg et 
al., 1986). Sometimes athymic, irradiated, bone marrow recon-
stituted mice were used (Berendt and North, 1980; Dye and North, 
1981). Since the T cell growth factor Interleukin 2 (IL-2) has 
become available (Morgan et al., 1976; Tanaguchi et al., 1983) 
the use of tn_yitro expanded immune T cells derived from spleen, 
draining lymph nodes or tumor infiltrate has been applied for 
adoptive transfer (rev. Rosenberg et al., 1986; Shu et al., 
1987; Chou and Shu, 1987). Another possibility is to augment 
cytotoxicity and to expand the presensitized effector population 
by means of a mixed lymphocyte tumor culture (MLTC) (Fernandez-
Cruz et al., 1980; Engers et al., 1984; Cheever et al., 1986). By 
this approach presumably the production of endogenous IL-2 by the 
T cells is stimulated. In these transfer studies cyclosphospha-
mide was often used to abrogate suppressor T function and 
diminish the tumor burden (rev. Rosenberg, 1984; rev. North, 
1985; rev. Evans, 1986). 
Additionally, regressing and progressing tumors have been 
analysed histologically (Evans, 1984; Martin et al., 1987). 
Variable frequencies of T cells were found, probably depending on 
the model used. A good correlation between the number of the 
(various) T cells and progression or regression of the tumor was 
not always evident. 
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From studies on the phenotype of the effector T lymphocytes 
in tumor rejection seemingly controversial results have been 
obtained (rev. Loveland and McKenzie, 1982; rev. North, 1985). In 
some studies Lyt-1-2+ CTLs were indicated as the major effector 
cell population (Leclerc and Cantor, 1980a; Engers et al., 1984; 
Fuyama et al., 1985; Mule et al., 1987). Others reported the 
requirement of Lyt-1+2- (L3T4) cells (Fernandez-Cruz et al., 
1980; Greenberg et al., 1981, Fujiwara et al., 1984; Bookman et 
al., 1987). A number of studies underlines the necessity of the 
presence of Lyt-1+2+ (3+) precursor cells (Shimizu and Shen, 
1979; Fuyama et al., 1986; Prat et al., 1983; Leclerc and Cantor, 
1980a) or both Lyt-1+2- (L3T4) and Lyt-2+(3+) (Cheever et al., 
1986; Chou and Shu, 1987). The Lyt-1+ and Lyt-2+ cells may then 
continuously be recruited from Lyt-1+2+3+ precursors (Shimizu and 
Shen, 1979; Leclerc and Cantor, 1980b). Lyt-1+ cells may either 
function as helper cells for Lyt-2+ CTL (Chou and Shu, 1987; 
Cheever et al., 1987) or as mediators of a delayed-type hypersen-
sitivity (DTH) response (Bookman et al., 1987). However, the 
effects of these cell types on tumor cells are uncertain and 
tumorgrowth seems to be controlled by a network of helper, 
cytotoxic and suppressor systems with the apparent involvement of 
complicated idiotypic interactions (rev. Schreiber, 1984; rev. 
North, 1985; rev. Robins, 1986; rev. Evans, 1986). 
4.4 Macrophage anti-tumor response 
The presence of macrophages in tumors is a well known pheno-
menon (rev. Den Otter, 1986). Since macrophages exert many func-
tions, the study of their effect on tumor growth is difficult. 
Macrophage activation proceeds through different stages via 
several sequential signals and these different stages are 
reflected by the expression of various receptors needed for the 
acquired functions (rev. Adams, 1982; Ralph et al., 1982; Johnson 
et al., 1983). Macrophages may act in a specific or non-specific 
way. 
In the immune system macrophages play a central role both as 
antigen presenting cells in the context of class II major histo-
compatibility gene products and by activating helper T cells by 
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interleukin 1 (rev. Buus et al., 1987). Macrophages are also 
reported to act in an immunosuppressive way (Fernandez-Cruz et 
al., 1982). They can also be rendered cytotoxic by the T cell 
mediated release of specific macrophage arming factor (Evans et 
al., 1973; Dullens et al., 1986) or non-specifically by macro-
phage activating factor (Piessens et al., 1981), which seems to 
be equivalent to gamma-interferon (Nakajima et al., 1985). 
An important finding was that macrophages may play an 
effector role in antibody dependent cellular cytotoxicity (ADCC), 
particularly demonstrated in immunotherapeutic models, either 
acting rapidly or slowly (Shin et al., 1975; Key and Haskill, 
1981b; Langlois et al., 1981; Steplewski et al., 1983; Adams et 
al., 1984). Rapidly acting ADCC is achieved in about 6-8 hours 
and apparently needs another activation stage than slowly acting 
ADCC, which has its maximum at 24-72 hours (Johnson et al., 
1986). 
4.5 Natural killer cell anti-tumor response 
According to Woodruff (1987) natural killer (NK) cells may be 
defined as cells other than macrophages and polymorphonuclear 
leukocytes derived from non-immunized animals which are cytotoxic 
for neoplastic targets in the absence of specific antibody. They 
may be divided into 2 subpopulations on the basis of their 
surface markers and their lytic activity in_vitro, which is for 
one class more rapid than for the other. Another division was 
introduced on the basis of genetic, phenotypical and functional 
differences in a) NK cells, belonging to a different lineage 
than T, B or myeloid cells; and b) non-MHC restricted CTL 
(Lanier et al., 1986). At least some NK cells have a similar 
morphology as large granular lymphocytes being particularly found 
in spleen, lymph nodes and peripheral blood and in lower frequen-
cies in newborn and old mice (Herberman et al., 1975, 1978; 
Kiessling et al., 1975). 
The nude mouse is 
(Minato et al., 1979). 
known to have considerable NK activity 
The susceptibility to primary tumors and 
tumor progression after inoculation of tumor cells is generally 
well-correlated to the absence of NK activity (rev. Woodruff, 
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1986). The exact working mechanism is unknown. NK cells can be 
stimulated by interferons (Gidlund et al., 1978). NK cells may 
have an active role in natural resistance, particularly in the 
case of virally induced tumors. This is likely due to the 
stimulatory action of interferon produced by these cells (rev. 
Den Otter, 1986). 
Since in the immunotherapeutical model described in this 
thesis virally induced tumors are used, the humoral and cellular 
immune response against leukemia viruses and virus-infected cells 
will be discussed separately. 
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5.1 Humoral response to MuLV 
Depending on the mouse strain, an antibody response is elici-
ted against exogenous ecotropic and dualtropic (MCF) viruses in 
newborn or adult mice (rev. Ihle and Lee, 1982; Zijlstra et al., 
1985). I~ general these responses are less effective in newborn 
mice which can therefore be more successfully infected than adult 
mice (McCoy et al., 1972). Also against endogenous ecotropic 
viruses antibody formation takes place, in contrast to endogenous 
xenotropic viruses to which detectable antibodies are rarely 
found (rev. Ihle et al., 1982). 
The antibody regulating genes have been mapped mainly to the 
H-2 complex (rev. Meruelo and Bach, 1983), but a regulatory role 
of non-H-2-linked loci also has been reported (Chesebro and 
Wehrly, 1979). The antibody response to activated endogenous 
ecotropic and MCF viruses is predominantly directed to gp70 and 
p15E, with neutralizing antibodies directed to type specific 
determinants of gp70 and non-neutralizing antibodies to group 
and/or interspecies specific determinants of p15E and gp70 (Ihle 
et al., 1974; Ihle and Lazar, 1977; rev. Ihle et al., 1982; 
Zijlstra et al., 1985). The antibody response to exogenous 
ecotropic viruses of the FMR group is also mainly directed to the 
envelope proteins, but antibodies against p30 and p12 may be 
present as well (rev. Ihle et al., 1982). A reverse correlation 
exists between antibody titers and the degree of viraemia, but 
the presence of neutralizing antibodies in infected and 
susceptible mice does not always prevent leukemogenesis (Vlug et 
al., 1980). 
5.2 Humoral response to MuLV-infected cells 
Apart from an antibody response directed against the virion 
itself a humoral response may be induced by cell surface antigens 
present on virally infected or transformed cells (Collins et al., 
1978; rev. Kurth et al., 1979; Weinhold et al., 1984). The H-2 
dependent generation of some of these antibodies has been 
established (Sato, 1973; Vlug et al., 1983). 
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Although a number of cell surface antigens already mentioned 
previously (3.12) is defined by hetero- or alloimmunization 
(rev. Old and Stockert, 1977), some of them display a strong 
immunogenicity in the syngeneic host. Particularly antigens 
shared by Friend, Moloney and Rauscher virus on infected or 
transformed cells belong to this group (Old et al., 1964a; rev. 
Old and Stockert, 1977). In mice with tumors induced by 
inoculation with the Mo-MuLV/MSV complex, a specific antibody 
response to these antigens is detectable, particularly in sera of 
mice with regressing tumors (rev. Levy and Leclerc, 1977). 
Cytotoxic antibodies to MuLV affected target cells may prevent 
leukemia by elimination of these cells (rev. Kurth et al., 1979; 
Vlug et al., 1983). 
5.3 T cell response to MuLV-infected or -transformed cells 
The recognition of MuLV related antigens in association with 
class I MHC products by CTL has been well documented (Gomard et 
al., 1976; Blank and Lilly, 1977; Stukartet al., 1982; rev. 
Doherty et al., 1984). The CTL response against MuLV-infected 
cells is determined both by the level of expression of H-2 anti-
gens and of the virus-encoded antigens (Plata et al., 1981; Flyer 
et al., 1983). Depending on the H-2 haplotype the CTL recognize 
the viral antigens in association with either K or D region 
determinants (Blank and Lilly, 1977; Gomard et al., 1980). The 
level of expression of viral antigens seems also to be affected 
by H-2 genes (Meruelo and Bach, 1983). The expression of H-2 
products themselves on infected cells is highly variable and 
depends on the mouse strain used. This expression can apparently 
be influenced by retroviral infection (Meruelo et al., 1978; 
Flyer et al., 1985). A CTL response to exogenous FMR MuLV can be 
easily detected in responder strains (Plata and Lilly, 1979), in 
contrast to the ecotropic AKR MuLV, which is endogenous to most 
strains of mice. A heterogeneous group of viral determi-nants 
can be recognized by MuLV specific CTL (Plata, 1982). In Gross 
and FMR MuLV-infected cells, envelope glycoproteins (Collins et 
al., 1980; Flyer et al., 1983; Plata et al., 1987) and 
(glycosylated) g~g (poly)proteins are recognized by CTL (Green, 
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1980; Plata et al., 1983; Vander Hoorn et al., 1986; Flyer et 
al., 1986; Plata et al., 1987). Initially it was assumed that for 
distinction between FMR and Gross virus induced tumors the same 
markers were recognized by CTL (Plata and Lilly, 1979; Plata, 
1982) as was found by serological typing (Old et al., 1964b). 
However, a recent study has suggested that this is only true for 
tumor-associated antigens, whereas FMR and Gross virus encoded 
proteins show cross-reactivity at the CTL levels (Flyer et al., 
1986). The antigenicity of these virus encoded proteins is 
apparently determined by class I MHC molecules, but the intensity 
and specificity of the immune response probably by genes outside 
the H-2 complex (Plata et al., 1987). 
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6.1 Introduction 
Manipulation of the immune system to destruct a tumor is an 
attractive perspective and has led to investigations on many 
fields. Gorer and Amos (1956) were among the first to demonstrate 
protection against a tumor challenge by the use of hyperimmune 
sera. These studies were followed by many others using syngeneic, 
allogeneic or heterologous antisera in animals and sometimes in 
humans (rev. Rosenberg and Terry, 1977). Protection could be 
demonstrated when antiserum was administered just prior to or 
following subcutaneous or intraperitoneal inoculation of tumor 
cells (Gorer and Amos, 1957; Moller, 1964). However, enhancement 
of tumor growth occurred as well, especially if sera were given 
prior to tumor injection (Mpller, 1964; Attia and Weiss, 1966). 
Treatment of established tumors was in general without effect 
except in some studies using sarcomas induced by the Mo-MuLV/MSV 
complex, which are known to be very immunogenic (Fefer, 1969; 
Hellstrom et al., 1969; rev. Levy and Leclerc, 1977). Also in 
humans a few, not well documented, successes have been claimed 
(Sumner and Foraker, 1960; Ngu et al., 1967). Successful therapy 
seemed particularly limited by lack of quantity and specificity 
of the immune sera. The development of the hybridoma technology 
raised new hope for the future (Kohler and Milstein, 1975). 
Since then a number of animal and human studies has been carried 
out, but with various results (rev. Foon et al., 1982). From 
these studies a number of factors became clear concerning the use 
of antibodies for therapy of cancer, which will be mentioned in 
the following paragraphs. 
6.2 Tumor-specific antigens 
Tumor specificity is dependent on the presence of antigens 
uniquely expressed on the tumor, to which antibodies or CTL can 
be directed. The search for specificity has been a disappointing 
one and has led to the conviction that save for a few exceptions 
as idiotype expression on B and T cell lymphomas (rev. Stevenson 
and Glennie, 1985), the majority of presumed tumor specific 
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antigenic determinants is expressed only in different frequencies 
on tumor and normal tissue. Besides that, it was realized that 
most tumors, although originally monoclonal, soon become hetero-
genous in many aspects as the result of mutation and selection of 
(faster growing) tumor cells (rev. Heppner, 1984). The problem 
of non-specificity is mainly managed by the use of xenografts on 
nude mice (Herlyn et al., 1980; Shouval et al., 1982; Mujoo et 
al., 1987) or by the use of virally, chemically or physically 
induced tumors, which have antigens not expressed on normal host 
tissues (Kennel et al., 1983; North and Dean, 1983; Key et al., 
1983). These artificially induced tumors may often consistently 
express tumor-associated antigens. 
Antigen loss in the cell population may be caused by select-
ion of tumor cells, which do not express this antigen (Young and 
Hakomori 1981), but also by antigenic modulation as first descri-
bed for the TL antigen on thymocytes (rev. Old, 1981). During 
modulation antigen-antibody complexes are redistributed and shed 
from the cell surface or internalized (rev. Chatenoud and Bach, 
1984). This phenomenon is specific and reexpression occurs after 
withdrawal of the implicated antibody. Antigenic modulation 
sometimes is the result of bivalent antibody binding as is 
described for idiotypic antigens on lymphomas (Elliott et al., 
1987). 
Antigenic modulation has implications for antibody therapy, 
which means that in these cases either an initial destruction of 
all tumor cells should be achieved or antibodies to different 
antigens should be used consecutively (rev. Chatenoud and Bach, 
1984). Otherwise the application of univalent antibodies could 
circumvent the problem of antigenic modulation. Univalent anti-
bodies can be obtained for instance by fusing immune spleen cells 
with myeloma cell lines which secrete non-compatible light chains 
(Cobbold and Waldmann, 1984). 
6.3 Type and density of antigens 
Depending on the target antigen, the antibody-antigen inter-
action may be inert or affect tumor growth. The latter may be due 
to growth inhibition and/or cytotoxicity. Antibodies directed to 
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the transferrin receptor (Sauvage et al., 1987), the epidermal 
growth factor receptor (Masui et al., 1984), as well as idiotypic 
determinants (Schreiber and Leibson, 1978) and sometimes not 
further identified antigens (Vollmers et al., 1985) have been 
shown to inhibit tumor growth tn vttro by specific antigen-
antibody interaction. 
Antigen density 'on tumor cells seems equally important for 
tumor destruction. When an ADCC mechanism is involved the 
magnitude of effector cell action is influenced (Herlyn et al., 
1985). According to the authors, the affinity of antibodies to 
their epitope appears to be less important. 
The obvious consequence for antibody therapy is selection of 
antibodies directed to antigens which are present in high 
densities. Alternatively a mixture of several monoclonal 
antibodies directed to different targets can be used. This 
approach has been shown to result in a better response (Herlyn et 
al., 1985; Ceriani et al., 1987) by the cooperation of different 
monoclonal antibodies mediating ADCC (Ralph and Nakoinz, 1984). 
This cooperation for ADCC may be the result of an increased 
amount of antibody due to binding at various epitopes. A higher 
binding affinity of some mixtures of monoclonal antibodies 
compared to the affinity of either individual antibody alone, 
however, has been demonstrated (Ehrlich et al., 1982). This 
mechanism also may lead to more antibodies bound to the cell 
surface and may thus contribute to a more effective ADCC. 
6.4 Accessibility of antibodies 
The accessibility of antibodies to a tumor is important. A 
number of studies has shown specific accumulation of antibodies 
labelled with radio-isotopes in the tumor (rev. Goldenberg and 
Deland, 1982; rev. Begent, 1985; rev. Ford and Casson, 1986). 
It has been shown that vascularisation is, as expected, an 
important issue (Sands et al, 1986). This is particularly demon-
strated by autoradiographic studies of subcutaneous tumors where 
antibody was preferentially found at the, best vascularized, 
tumor-host interface (Moshakis et al., 1981; Epenetos et al., 
1982). It can therefore be expected that small tumor foci in 
32 
well-vascularized organs are best accessible to administered 
antibodies (see Chapter III). 
6.5 Species and isotype of the antibody 
It has been established that the antibody class and subclass 
may affect the final outcome of tumor therapy with monoclonal 
antibodies. Particularly IgG2a monoclonal antibodies have been 
shown to be effective (Herlyn and Koprowski, 1982; Adams et al., 
1984; Denkers et al., 1985; Berinstein and Levy, 1987), similarly 
as earlier reported for polyclonal IgG2a antibodies (Matthews et 
al., 1981). Presumably ADCC is the major effector mechanism and 
although all IgG antibody classes have the ability to mediate 
ADCC (Ralph and Nakoinz, 1983), IgG2a antibodies have been proven 
to be 
1981; 
particularly effective in this process (Langlois et al., 
Kipps et al., 1985; Johnson et al., 1986). IgG2a and IgM 
are known to fix complement (C1) and may mediate CDC effectively 
in mice (Roitt et al., 1985). 
The species of the antibody is important with respect to 
sensitization as is the case for xenogeneic or allogeneic anti-
bodies (Villemain et al., 1986; Benjamin et al., 1986). Anti-
idiotypic antibodies may arise, which could abrogate the 
therapeutic effect by blocking the tumor directed antibody or 
provoke a hypersensitivity reaction (rev. Chatenoud, 1986). 
6.6 Quantity of antibodies and frequency of administration 
The quantity of antibodies needed for tumor therapy has not 
been assessed extensively in most studies and is probably 
dependent on a number of factors as for instance antibody 
(sub)class, tumor load, accessibility, antigen density and 
circulating antigen. In most studies therapy is started just 
after tumor inoculation (Bernstein et al., 1980; Kirch and 
Hammerling, 1981; Sauvage et al., 1987). In contrast only few 
authors studied the effect of therapy on an established tumor 
burden (Badger et al., 1986). Unpurified ascites preparations or 
purified antibodies were used, the content of a single dose 
ranging from ~ 1 ~g to ~ 6 mg antibody (Scheinberg and Strand, 
1982; Badger and Bernstein, 1983). Detrimental effects of very 
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high doses were seen (Badger and Bernstein, 1983) as previously 
shown in models using polyclonal antibodies (Lanier et al., 
1979). With respect to the frequency of administration of 
antibody, some authors report one single injection being equal to 
a multiple dose regimen (Kirch and Hammerling, 1981; Badger and 
Bernstein, 1983; see Chapter IV), whereas others claim the 
necessity of multiple injections (Sauvage et al., 1987). Some 
studies included data on antibody clearance in their approach to 
define a dose regimen (Scheinberg and Strand, 1982; Denkers et 
al., 1985). Apparently each model has its own specific require-
ments and general rules for dose regimens are not available yet. 
6.7 Effector mechanisms 
As mentioned already, the mechanism by which antibodies 
affect tumor destruction is generally thought to be based mainly 
on ADCC. It is presumed that ADCC is mediated particularly by 
macrophages (Shin et al., 1975; Johnson et al., 1979). This 
presumption is mainly based on analyses of tumor infiltrates in 
which they were present in high numbers (Key and Haskill, 1981b; 
Adams et al., 1984), whereas their ability to mediate ADCC was 
shown by io vitro studies (Nathan et al., 1980; Kawase et al., 
1985; Johnson et al., 1986). Iu_v1vo studies of appropriate 
(nude) mouse models confirmed this view (Herlyn and Koprowski, 
1982; Steplewski et al., 1983). The effectiveness of antibody 
therapy in C5 deficient mice (Lanier et al., 1980; Badger and 
Bernstein, 1983) or artificially complement depleted mice (Kennel 
et al., 1985) made an important role for CDC less likely. A 
contributive role of CDC, however, is not 
(rev. Lamon, 1974; Capone et al., 1983). 
Based on the present information 
excluded in some models 
available, successful 
immunotherapy with unmodified monoclonal antibodies may be only 
expected in a non-immunocompromised host. In this context not 
only the number of effector cells is important but also their 
functional activity, which may be abrogated in some cases due to 
for instance antigen-antibody complexes (rev. Hellstrom and 
Hellstrom, 1974). Shortage of effector cells may not be restric-
ted to conditions of systemic suppression, but may also be a 
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local obstacle to successful immunotherapy as has been described 
for large tumors (Johnson et al., 1979). 
6.8 Future aspects of monoclonal antibody therapy 
Although monoclonal antibody therapy of malignant disease 
seems promising in a number of studies (rev. Foon et al., 1982), 
further developments are required to improve the final outcome. 
Several approaches are currently followed: 
Tbe u§e of: 
Syb~egueot injectiQns _of monoglog9l antioo~ies to different 
target antigens (rev. Chatenoud and Bach, 1984) or univalent 
antibodies (Cobbold and Waldmann, 1984) to prevent modulation 
of tumor associated antigens. 
~ mi~tur~_of several monoclonal _agtibggi~§ with 
epitope specificities to prevent immunoselection 
enhance ADCC (Ceriani et al., 1987). 
different 
and to 
Syngeneic_autioo~ies (this thesis) to avoid an anti-immuno-
globulin reaction. The preparation of syngeneic human 
monoclonal antibodies from lymphocytes of patients with 
cancer and their subsequent use for treatment seems to yield 
generally few tumor specific responses (rev. Beverley and 
Riethmuller, 1987). 
Chimeric antibodies. Constructs of antibodies in which only 
the idiotype regions are of xenogeneic origin (rev. Beverley 
and Riethmuller, 1987). This approach should prevent anti-
antibody response, while retaining high specificity by the 
xenogeneic immunization procedure (rev. Chatenoud, 1986). 
ijybrid antibodies. Constructs of antibodies with one site for 
tumor specific binding and one site directed to the CTL 
antigen receptor to enhance cell mediated cytotoxicity 
(Staerz eta~., 1985; Perez et al., 1987). The injection of 
IL-2 activated mononuclear killer cells "armed" (by 
incubation) with specific monoclonal antibodies is a 
variation on this ADCC theme (Honsik et al., 1987). 
Immupgtoxin§ __ ang_-ch~IDQtherapeutics. Antibodies are coupled 
to toxins or chemotherapeutics. The aim is targeting of these 
toxins (ricin, abrin, diphteriatoxin, etc.) or chemotherapeu-
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tical agents (chlorambucil, methotrexate, etc.) to the tumor 
site in order to obtain specific tumor destruction (rev. 
Pastan et al., 1986; rev. Ford and Casson, 1986). 
Immungradiotberapy. Specific tumor destruction is here caused 
by a, {3 and 'Y -radiation from isotopes coupled to monoclonal 
antibodies (rev. Order, 1981,; rev. Ford and Casson, 1986). 
A similar approach can equally be used for tumor imaging 
(chapter III; rev. Begent, 1985). 
Immuogmodulstion. Tumor destruction can be induced by 
activating the appropriate effector cell subset. 
Immunotherapy by means of stimulation of Lyt-1+2- cells, 
using monoclonal antibodies directed to these cells has been 
described (Hollander, 1984). Otherwise antibodies can be used 
to eliminate undesirable (suppressor) T cell subsets (Cobbold 
et al., 1984). Another approach is to manipulate idiotype 
network systems by anti-idiotype monoclonal antibodies 
activating silent lymphocyte clones, which may elicit a DTH 
reaction against the tumor (Forstrom et al., 1984; Nelson et 
al., 1987; rev. Lee et al., 1986) or utilize anti-idiotype 
antibodies as a vaccine against the tumor (Raychaudhuri et 
al., 1986; rev. Lee et al., 1986). 
CQWbination tberapy. Improvement of monoclonal antibody 
therapy may be obtained by simultaneous injection with immune 
modulating lymphokines as IL-2 (Berinstein and Levy, 1987), 
alpha-interferon (Basham et al., 1987), or by combination 
with chemotherapeutical agents (Weill-Hillman et al., 1987). 
It is clear that this list is incomplete and even 
sophisticated approaches will be developed in the future. 
more 
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Hybridomas producing syngeneic monoclonal antibodies (MAbs) 
were prepared by fusion of spleen cells of BALB/c mice, which 
were immunized with sublethal doses of RMB-1 cells. This cell 
line originates from a Rauscher virus (R-MuLV)-induced myeloid 
leukemia and forms tumors when re-inoculated into mice. MAbs 
were characterized as 
and non-virally induced 
4D2B4 were analyzed 
regards their reactivity against virally 
cell lines. Two selected MAbs IC5F5 and 
further. Their binding to subcellular 
structures was determined, and so were the properties of the 
antigens to which they are directed. MAb IC5F5 is of the IgG2a 
and 4D2B4 of the IgG2b subclass. Both bind to R-MuLV-infected or 
-transformed cell lines and are not mutually competitive. The 
antibodies do not react with other murine and human myeloid 
leukemic cells. As shown by immune-electron microscopy, these 
MAbs have affinity to the cell membrane of non-virus producing 
RMB-1 cells. When lysates of purified virus were analyzed, the 
MAbs were found to be directed to the g~g precursor protein Pr65, 
and one of them (IC5F5) also to be directed to the core protein 
p12. In RMB-1 cells, binding occurs to a 50 kDa glycoprotein and 
2 proteins of 26 and 29 kDa. Since RMB-1 cells do not produce 
virus, but express aberrant viral proteins, these MAbs are tumor-
specific and useful for immunotherapy. 
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JNTijODUCTION 
There has been considerable speculation on the nature and 
even the existence of tumor-specific antigens since their 
introduction into oncology. A number of these tumor-associated 
antigens are virtually absent from the normal tissue of the adult 
organism, but are present in fetal tissues. Therefore it is 
assumed that tumor cells carrying these antigens are clonally 
expanded after oncogenic transformation (Greaves and Yanossy, 
1978; Ibsen and Fischman, 1979). This is not true for cells 
transformed by many tumor viruses. In this type of cells, viral 
and transforming proteins are synthesized by newly inserted genes 
(Bishop, 1987). For instance, in cells infected by Reus sarcoma, 
virus transformation may result in the induction of antibody 
formation against both viral and transforming proteins (Erickson, 
1980). On the other hand, with chronic retroviruses, which do 
not carry oncogenes, antibody formation is predominantly directed 
against viral envelope glycoproteins. This antibody formation is 
largely dependent on the genetic constitution of th~ infected 
mice (Ihle et al., 1982). However, the induction of specific 
virus-associated antigens has also been reported in Friend, 
Moloney and Rauscher leukemias (Old et al., 1964; Chesebro et 
al., 1981; Rogers et al., 1984). Most likely these antigens are 
abnormally processed glycosylated viral core proteins present in 
infected cells but not in the virion itself (Weiss et al., 1982). 
In general, antibody formation against viral and virus-
associated antigens is insufficient to prevent acute leukemias as 
is the case for Rauscher virus-induced erythroid leukemia 
(Rauscher, 1962), but an immune reaction prevents chronic 
leukemias when adult mice are injected with helper virus (McCoy 
et al., 1972). In contrast, when mice are infected neonatally, 
lymphatic or myeloid leukemias are induced, but after a much 
longer latency and with a much lower frequency. From one of these 
leukemias a transplantable myeloid leukemic cell line (RMB-1) was 
established, which has been adapted to grow permanently in vitro 
(de Both et al., 1981, 1985). 
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When adult mice were repeatedly injected with sublethal doses 
of RMB-1 cells, an immune response against these cells was detec-
ted in their sera. We decided therefore to prepare syngeneic MAbs 
for immunotherapeutic purposes. In this report we describe the 
properties of these antibodies and of the corresponding antigens. 
Animals 
Six-week-old male and female BALB/c mice were obtained from 
TNO, Zeist, The Netherlands. Primary erythroid leukemias were 
induced by injecting of cell-free extracts from leukemic spleen 
tissue in a 1:4 volume (w/v) in phosphate-buffered saline (PBS). 
Tumors were obtained after subcutaneous or intravenous injection 
with 10 7 myeloid leukemic RMB-1 cells. 
Viruses 
Viruses were purified according to the method of Duesberg and 
Robinson (1966) from culture fluids of the Rauscher virus produ-
cing cell lines 3T3CL9 (Mol et al., 1982) and JLSV5 (Wright and 
Lasfargues, 1965), and from the Friend-virus-producing cell line 
643/22N provided by Dr. I.B. Pragnell, Beatson Institute, 
Glasgow, Scotland and from Moloney-virus-infected NIH 3T3 cells 
provided by Dr. P. Bentvelzen, TNO, Rijswijk, The Netherlands. AKR 
virus was a gift from Dr. A. Berns, Netherlands Cancer Institute, 
Amsterdam. 
Cell lines 
For Rauscher-virus-transformed cell lines, the erythroid 
(RED-1), the lymphatic (RLD-1) and the myeloid (RMB-1) cell lines 
were used (de Both et al., 1978, 1981, 1983). As non-virally 
induced myeloid leukemic cells the murine cell line WEHI-3B was 
used (Metcalf et al., 1969). Cell suspensions of thymocytes of 6-
week-old mice and erythroblasts from spleens of mice recovering 
from anemia induced by 2 consecutive daily injections of 0.2 ml 
of a 1.25% solution of phenylhydrazine in PBS were used as 
controls. Macrophages were obtained by an intraperitoneal inject-
ion of 5 ml Hanks balanced salt solution (HBSS) and aspiration of 
the fluid. Before use all cells were washed 3 times in HBSS. As 
70 
non-virus-producing fibroblastic cells we used 3T3 cells. All 
cell lines were cultured either in RPMI 1640 or in Dulbecco's 
minimum essential medium (Gibco) supplemented with 10% fetal calf 
serum and 100 IU/ml penicillin and 10 ~g/ml streptomycin. 
~oti§e~a 
Goat 
anti-gp70, 
antisera 
-p30, 
against Rauscher 
-p15, -p12 and -p10, 
viral proteins were: 
which were a gift from 
Dr. Varrato, Biological Carcinogenesis Branch, NIH, Bethesda, MD. 
Rabbit-anti-p15E was a gift from Dr. W. van der Ven, University 
of Nljmegen, The Netherlands. 
~~b~ ~og_~§gtte~ 
In general, the procedure for the production of MAbs as 
described by Kohler and Milstein (1975) was followed. Adult 
BALB/c mice were inoculated s.c. with sublethal doses of RMB-1 
cells once every 4 weeks for a 3 month period. After a final i.v. 
booster, sera were screened in an enzyme-linked immunosorbent 
assay (ELISA, see below) for antibody production against RMB-1 
cells. If positive, the spleen cells were fused with the 
P3-X 63-Ag8.653 BALB/c myeloma cell line. 
The hybridomas were screened for antibody production by 
testing the supernatants in an ELISA. Selected hybridomas were 
subcloned by endpoint dilution and brought in ascites by 
injecting 15 x 106 hybridoma cells intraperitoneally in BALB/c 
mice, primed with 0.5 ml Pristane (Janssen, Beerse, Belgium) 
10-21 days before. 
~tg~g-~LJSA sy§te~ 
Screening of antibodies was carried out by a semi-quantitati-
ve ELISA on Terasaki microtiter well plates using ~-galactosida­
se linked sheep anti-mouse IgG (Amersham, Houten, The Nether-
lands) as described by Van Soest et al. (1984). As a reference 
for fluorescence 0.1 ~M/ml methyl-umbelliferon was used. As 
positive control for RMB-1 cells anti-T200 was used. 
Im~~oope~oxida§e_§t~ioiog 
Paraffin-embedded or frozen tissues of healthy control mice, 
and of leukemic and tumor bearing mice, were stained in a 2-step 
reaction, using antibody-containing supernatant and horse-radish 
peroxidase conjugated to rabbit anti-mouse IgG (dilution 1:100). 
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As substrate, diaminobenzidine (500 ~g/ml) +3% H2o2 in PBS was 
added. Tissues were counterstained with hematoxylin. 
Deter~iu~tiou_of_i~~yuoglooYliu cl~§§e§ aud_§yocl~s§e§ 
In an Ouchterlony double immunodiffusion assay the immunoglo-
bulin (sub)class of the MAbs was determined by diffusion in agar 
of the antibodies against rabbit anti-IgA, -IgM, -IgG, -IgG1, 
-IgG2a, -IgG2b and IgG3 (Nordic, Tilburg, The Netherlands) and 
subsequently stained with Coomassie Brilliant Blue (1%) in PBS. 
furificatiou_~gg_iQ9;D;~~t;gn_Qf_~~b~ 
MAbs were purified by gel filtration on a DEAE-Sephacel 
column (Pharmacia, Uppsala, Sweden) and by protein A-Sepharose 
affinity chromatography (Pharmacia) according to Ey et al. 
(1978). 
The method of Bolton and Hunter (1973) was used to prepare 
100 ~g 125 I-1abelled MAbs. The antibody was freed from unbound 
125r by gel filtration on a Sephadex G50 column in PBS and stored 
at 4°C. The iodinized MAbs had a maximal specific activity of 
4 mCi/nMol and proved to be biologically active in a solid-phase 
radioimmuno assay and were electrophoretically pure. 
~utigeu 9eterminatiou 
Virus lysates, lysates of whole RMB-1 and WEHI-3B cells, were 
made in 10 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Nonidet (NP-40), 
1 mM pheny1methylsulphonyl-fluoride (PMSF) + 0.01% leupeptin. 
After treatment with sodium dodecylsulphate (SDS) electrophoresis 
was carried out using 12.5% polyacrylamide gels. The gels were 
blotted on nitrocellulose filter (Millipore) according to 
Burnette (1981). The filters were incubated with either mono- or 
polyclonal antisera using 125I-labelled protein-A (Amersham) as 
second step, or directly incubated with 125I-labelled MAbs. After 
repeated washes the antigen-antibody complexes were visualized by 
autoradiography. The presence of proteins on the filters was 
verified by staining with amido black. 
To verify whether the antigen was glycosylated or not, cell 
lysates were loaded on an antibody column prepared by coupling 
the antibody to CNBr Sepharose (Pharmacia). Antigen was eluted 
from the column with 3M KSCN in PBS, the eluate was dialyzed 
overnight at 4°C against 500 volumes of PBS, concentrated with 
72 
Amicon Centricon-10 tubes and analyzed in Western b~ots. 
Glycosylation of proteins could be shown by staining according to 
Clegg (1982). 
Cowpetttiou_~?dioiwwYUQ_?s~ay 
Microtiter well trays coated with RMB-1 were 
different dilutions of IC5F5 and 4D2B4 ascites in 
for 1 hr at 37°C. After several washes with PBS + 
incubated with 
PBS + 2% BSA 
0.02% gelatin 
trays of both series were incubated with saturating dilutions of 
125 I-labelled IC5F5 or 4D2B4 in PBS + 2% BSA for 1 hr at 37°C. 
After thoroughly washing, the wells were cut out and counted in a 
LKB gamma counter. Results are expressed as percentage of amount 
of radioactivity bound by non-preincubated cells. The competition 
was considered positive when a decrease of radioactivity less 
than 50% of the maximal binding was measured with increasing 
concentration of unlabelled MAbs. 
autigen deu~tty 
Antigen density and affinity was determined according to 
Scatchard (1949). Briefly, RMB-1 cells were incubated in a total 
volume of 100 pl 20 mM HEPES in HBSS plus 0.125% gelatin contain-
ing various amounts of 125 I-IC5F5 (0.01-10 nM) for 90 min at room 
temperature. For the determination of non-specifically bound 
125 I-IC5F5, cells were incubated with various amounts of 
125 I-IC5F5 in the presence of (1 x 10 6 M) unlabelled IC5F5. After 
incubation, the cells were washed with ice-cold HBSS plus HEPES 
to remove unbound IC5F5. Radioactivity bound to the cells was 
determined in an LKB-1280 ultragamma counter. 
JWWYU07elegt~on_WlQ~Q~QQPY 
Two million RMB-1 and RLD-1 cells were suspended and fixed in 
1.5% v/v paraformaldehyde + 0.1% v/v glutaraldehyde buffered in 
0.1 M sodium phosphate buffer, pH 7.2, at 0-4°C for 1 hr. After 
washing, the pellet was resuspended in 2% agar (Difco, Detroit, 
MI) and treated further according to Daems and Koerten (1978). 
The agar pellet was minced into 1 mm cubes and embedded in 
Lowicryl K4M (Balzers, Liechtenstein) at -40°C. Ultra-thin 
Lowicryl sections were collected on carbon-coated Formvar-filmed 
mesh 100 copper grids. Virus was directly dried on the same type 
of grids. Visualization of the MAbs was realized with 10 nM 
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colloidal gold coated with goat anti-mouse antiserum (Janssen). 
As control, phosphate buffer was used instead of MAb, Sections 
were stained with uranyl acetate and lead citrate. Transmission 
micrographs were made on a Philips EM 300 electron microscope at 
80 kV. 
P~oductio~-~~g_select1on of_~~g~ 
In the sera of mice immunized with sublethal doses of RMB-1 
cells a syngeneic immune reaction against tumor cells can be 
detected. Six out of 600 hybridomas made from the spleens of 
these mice were selected. These hybridomas produced MAbs against 
Rauscher-induced myeloid leukemic (RMB-1) cells, but not against 
control erythroblasts, thymocytes and macrophages. Two MAbs, IC5 
and 4D2, were subcloned and 2 subclones IC5F5 and 4D2B4 were 
selected. The results shown in Figure 1 demonstrate that the 
binding is restricted to the Rauscher virus-transformed or 
Rauscher virus-producing cell lines with the highest affinity for 
the RMB-1 cell line against which the antibodies were prepared. 
Both antibodies had identical reaction patterns, IC5F5 displaying 
the most pronounced activity. In an Ouchterlony double diffusion 
assay IC5F5 was shown to be of the IgG2a and 4D2B4 of the IgG2b 
subclass. 
J~~ynopero~ig~se_st~i~i~g 
Since one of the reasons for generating the MAbs was the need 
for application in an immunotherapy model, we investigated their 
affinity to tumor versus control tissues and the intracellular 
antigen distribution. The immunoperoxidase assay was carried out 
on liquid-nitrogen-frozen or paraffin-embedded tissue of fetal 
and adult control mice or RMB-1 tumor bearing adult mice. In all 
cases for IC5F5 (Fig. 2) a strong and for 4D2B4 a weaker reacti-
vity was observed for tumor cells, whereas control tissue 
remained negative. 
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Fig. 1. Reactivity of monoclonal antibodies ICSFS (a) and 4D2B4 (b) with 
R-MuLV infected and uninfected cell lines. Data from ELISAs are expressed 
as percentage of fluorescence of standard (100%) of 0.1 ~M/ml Methylumbelli-
feron. RED-1, Rauscher virus induced erythroid leukemic cells: RMB-1, myeloid 
leukemic cells; RLD-1, RLB lymphatic leukemic cells. JLSVS, Rauscher virus 
producing cell line: 3T3-CL9, Rauscher helper-virus-producing cell line: 
WEHI, non-virally induced myeloid leukemic cells. 
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Fig. 2. Immunoperoxi-
dase staining of 
ICSFS in liver section 
of a mouse injected 3 
days previously with 
myeloid leukemic cells 
Fig. 3. Immune-elec-
tron microscopy of 
cells incubated with 
ICSFS and gold labelled 
goat anti-mouse IgG: 
(a) non virus producing 
RMB-1 cells; (b) 
virus producing RLD-1 
cells. 
b 
I~muno=elect~ou mic~oscopy 
The membrane-bound localization of IC5F5 in RMB-1 cells was 
demonstrated in more detail by immuno-electron microscopy. As 
seen in Figure 3 many gold particles were present along the cell 
membrane of this non-producer cell line. Immuno-electron micros-
copy of the virus-producing, transformed cell line RLD-1 demon-
strated concentration of gold label around budding and free virus 
particles. With 4D2B4 a similar distribution was found. 
Antigep_gete~~iuation 
a~- Bauscber vi~u~. Since the antigen is virus-associated, 
as shown by the foregoing results, 125 I-labelled antibodies were 
tested against R-MuLV lysates using the Western blot technique. 
Simultaneously these lysates were tested with polyclonal antisera 
directed against the known viral proteins p10, p12, p15, p30, 
gp70 and p15E. 
r 
94k 
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m 6 7 8 
b 
Fig. 4. Screening of R-MuLV lysates with IC5F5 (a) and 4D2B4 (b) and differ-
ent antiviral antisera. (a) M = markers; lane 1, IC5F5; lane 2, anti-pl2; 
lane 3, anti-pl5; lane 4, anti-gp70; lane 5, anti-pl5E. (b) M = markers; 
lane 6, 4D2B4; lane 7, anti-p30; lane 8, anti-plO. 
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As shown in Figure 4, IC5F5 shows a binding activity identical to 
that of the p12 sera, intensively staining the g~g precursor 
Pr65gag, a doublet at 29 kDa (probably identical to the precursor 
Pr27gag) and a low-molecular weight protein. The pattern is 
identical to that of anti-p12. The relatively large amount of 
viral precursor proteins was in accordance with 50-70% immature 
particles in our virus preparations (electron microscopic data 
not shown). In addition to staining of p15, the precursor 
proteins Pr65gag and Pr27gag were stained weakly by anti-p15 
sera. With 4D2B4 only, affinity was found for the precursor 
Pr27gag and Pr65gag proteins but not for p12. 
To determine the virus specificity lysates of R-MuLV, F-MuLV, 
Mo-MuLV and AKR virus were tested by Western blotting against 
IC5F5 and 4D2B4. R-MuLV and F-MuLV were recognized by both MAbs. 
~~--R~~=J_gells. Since the antibodies were generated against 
the RMB-1 cell line, lysates of RMB-1 were compared with lysates 
of the non-virally-induced WEHI-3B myeloid cell line as control. 
As reference, lysates of R-MuLV were tested simultaneously. As 
shown in Figure 5, a cluster of bands was detected in RMB-1 with 
125 I-labelled IC5F5 showing molecular weights between 48 and 
50 kDa. Besides these proteins, 2 circumscript bands were recog-
nized at 29 and 25 kDa. The 29 kDa band is probably also identi-
cal to the Pr27gag. The low-molecular-weight p12 protein was 
never detected in cell lysates. 125 r-4D2B4 showed only a very 
weak band of 50 kDa which was hardly visible even after a long 
exposure time. The WEHI-3B cell lysate did not stain at all with 
either IC5F5 or 4D2B4. 
Staining of the glycosylated residues on the Western blot 
filters as described in "Material and Methods", showed a positive 
reaction with the 50 kDa protein in RMB-1 lysates, eluted from an 
affinity column to which the MAbs IC5F5 was bound, whereas the 29 
and 26 kDa proteins did not stain (Fig. 6). These results 
indicate that at least some of the proteins recognized on RMB-1 
by IC5F5 do not belong to the known (precursor) viral proteins 
and suggest a membrane-bound glycosylated polyprotein of 50 kDa 
expressing p12 determinants. 
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Fig. 5. Screening of lysates 
of R-MuLV (lanes 1,4), induced 
RMB-1 cells (lanes 2,5), and 
non-virus induced myeloid leukemic 
(WEHI) cells (lanes 3,6) with 
125r-labelled IC5F5 and 4D2B4. 
-Gp70 
-GpSO 
2 3 
Fig. 6. Glycoprotein staining 
of antigens eluted from a Sepha-
rose CNBr column to which IC5F5 
was bound. Lane l, total lysates 
of RMB-1 cells: lane 2-eluate 
-id; lane 3, viral lysate con-
taining gp70 as positive control. 
However, the fact that IC5F5 also detects non-glycosylated 
precursors indicates that the epitope itself is not composed of 
carbohydrate residues. 
Epitope_~p~gtftcity 
As shown by the Western blots both antibodies recognize the 
same precursor proteins Pr65gag and Pr27gag. A radio-immuno 
competition assay was undertaken to define the epitope specifi-
city. Figure 7 indicates that auto-competition could be provoked 
by pre-incubation with dilutions of identical, unlabelled MAbs. 
In the case of IC5F5, 85% loss of radioactivity was achieved by 
auto-competition (a), whereas with 4D2B4 this could be replaced 
for 60% of its maximal binding (b). Pre-incubation with the 
alternative unlabelled antibody did not inhibit binding of the 
other labelled antibody. Apparently both MAbs are directed 
against 2 different antigens or 2 different epitopes on the same 
antigen. 
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Antig~u_d~nsity 
One of both MAbs IC5F5 was 
the density of the antigen 
selected for immunotherapy. Since 
may be important for effective 
therapy, 
Figure 8. 
a Scatchard analysis was carried out which is shown in 
A specific binding of 90-95% of the 125 I-labelled Mab 
was shown. The number of binding sites was calculated to be 
1.8 x 105 /cell with an affinity constant (Ka) of 7.4 x 10 81/mol. 
DISCUSSION 
When Rauscher helper virus induced myeloid leukemic cells are 
transplanted syngeneically in adult mice an immune response is 
evoked against these cells. This allows the production of MAbs 
from spleens of mice repeatedly injected with lysates or 
sublethal doses of these tumor cells. 
During the last 2 decades several studies have been published 
on related subjects. Bianco et al. (1966) described an immune 
response of mice injected with X-irradiated virally induced 
lymphoma cells resulting in a resistance to subsequent trans-
plants mediated by cytotoxic and virus-neutralizing antibodies. 
After infection, C57Bl mice initially show a progression of 
chronic leukemia, but this phase is followed by regression of the 
leukemia and recovery of the animal. Young BALB/c mice are 
susceptible to Mo-MuLV, while older mice are not (Fefer et al., 
1967). An antigen called FMR, which was shared by cells infected 
with Friend, Moloney and Rauscher virus (Old et al., 1964), was 
thought to be responsible for this observation. 
Some authors suggest that such antigens are only associated 
with tumor virus infection and are not a part of viral proteins. 
Alaba et al. (1979) described syngeneic antibody formation after 
infection of BALB/c and C57Bl mice with Rauscher virus. These 
antibodies were directed against non-viral proteins of 46 and 
21 kDa. In a number of studies Rogers (1978, 1984) showed 
evidence that the FMR antigen is a glycoprotein of 175 kDa, which 
can be physically separated from viral proteins. Immunization 
with gp175 prevents the outgrowth of transplanted tumor cells by 
the formation of cytotoxic antibodies. 
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Other authors stress the importance of viral proteins in 
causing the induction of anti-FMR antibodies (Strand et al., 
1974; Nowinski et al., 1978; Chesebro et al., 1981), gp70 and p15 
being the main candidates. 
In the present study 2 MAbs are described reacting with p12 
in purified virus and with proteins of 65 and 27 kDa, which are 
precursors of p12 (Van Zaane et al~, 1976; Naso et al., 1979; 
Yoshinaka et al., 1980). 
A syngeneic Mab reacting with p12 was prepared by Chesebro et 
al. (1983) from mice recovering from Friend leukemia. Other 
investigators have isolated anti-p12 MAbs following xenogeneic 
immunization (Gambke et al., 1984; Pillemer et al., 1986). These 
MAbs had anti-FMR activity. Our 2 MAbs had affinity only to the 
related Friend virus, but not to Moloney or AKR virus. 
In RMB-1 cells a 50, 29 and (inconsistently) a 26 kDa band 
bind to IC5F5, but no binding to Pr65 was observed. The 50 kDa 
protein is a glycoprotein. The absence of p12 in RMB-1 cells 
(Fig. 5) is probably due to the fact that these cells do not 
produce virus. 
Some authors suggest that high-molecular-weight glycoproteins 
gp95gag and gp85gag synthesized from a Pr75 (Tung et al., 1977) 
can be converted into a number of glycoproteins ranging from gp55 
to gp27 (Fibbing et al., 1981) including gp45 and gp40 (Naso et 
al., 1983; Pillemer et al., 1986). 
Immune-electron microscopy indicates that 
which IC5F5 and 4D2B4 are directed is localized in 
the antigen to 
the membrane 
of RMB-1 cells. Scatchard analysis showed a high association 
constant and a number of 1.8 x 10 5 binding sites. Since the MAbs, 
bind to aberrant processed (glyco)proteins sharing p12 epitopes, 
it is likely that these proteins are incorporated in the cell 
membrane. In virus producing RLD-1 cells, IC5F5 binds especially 
to the budding particles, perhaps due to the presence of p12 or 
its precursor proteins. These findings are at variance to those 
of Schwarz et al. (1976) who found abundant presence of p12 in 
the cellular membrane of C-virus producing cells, but not on 
membranes of non-producing cells. 
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Only a few reports deal with the establishment of syngeneic 
MAbs. Kennel et al. (1985) have reported the isolation of MAbs 
directed against a non-viral 65 kDa protein in Moloney virus-
induced sarcomas. Syngeneic MAbs are also made from animals with 
non-virally induced tumors, as for instance in animals bearing a 
Lewis lung carcinoma (Midoux et al., 1984) or in mice injected 
with the B16 melanoma (Vollmers et al., 1985). 
Due to their high specificity, such syngeneic MAbs are excel-
lent tools for analysis of the mechanisms underlying 
immunological destruction of tumor cells. 
Ultimately, they offer the possibility of direct immuno-
therapy without the occurrence of strong anti-antibody reactions. 
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SU~ARY 
The binding of the syngeneic monoclonal antibodies IC5F5 and 
4D2B4 to Rauscher virus induced myeloid leukemic (RMB-1) cells 
was analyzed in_vivo in tumor bearing BALB/c mice. 
To verify if these antibodies bind specifically to RMB-1 
125 
cells, purified antibodies were iodinated with the isotopes I 
and 131 r. Mice previously inoculated with tumor cells were 
injected with these labelled monoclonal antibodies and the plasma 
clearance as well as the tissue distribution was determined. 
The clearance in tumor bearing animals was faster than in 
control mice. The tissue distribution was corrected for non-
specific accumulation by scoring for an unrelated antibody. 
Calculation of a localization index showed that IC5F5 binds at 
least 4.5 times more specifically to tumor cells than to other 
tissues. 
A preferential localization of radioactivity in subcutaneous 
tumor tissue was seen in the scanning of animals injected with 
131 r-labelled antibodies. 
The most direct proof of specific binding was observed in 
autoradiograms of animals treated with 125!-labelled antibodies. 
Small islands of tumor cells in the livers of mice inoculated 
intravenously both tumor cells had a high density of grains 
compared to other tissues and also compared to tumor cells in 
mice treated with unrelated monoclonal antibodies. 
These results show an efficient targeting of these monoclonal 
antibodies and make an immunotherapy of these myeloid leukemic 
cells possible. 
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IWT~ODUCTION 
The development of the hybridoma technology by Kohler and 
Milstein (21) has resulted in the production of monoclonal 
antibodies against assorted tumor cells. These antibodies have 
been used both for the detection and therapy of cancer. For 
instance the use of highly sensitive autoradiographic techniques 
allows the detection of radiolabelled monoclonal antibodies in 
tumor tissue (13,24,30). Also, by in vivo scanning tumor cells 
may be localized by monoclonal antibodies bound to radioactive 
isotopes (1,4,33). 
For the treatment of tumors mostly heterologous or allogeneic 
monoclonal antibodies have been used with the drawback that these 
antibodies were not completely tumor specific and were directed 
against differentiation antigens. For this reason its 
application is mainly restricted to antigens expressed in large 
amounts by certain tumors such as the carcino-embryonic antigen 
(CEA), human chorionic gonadotrophin and a-fetoprotein (14). 
Moreover, these xenogeneic antibodies evoke an anti-antibody 
formation, which may interfere with prolonged immunotherapy. 
In a previous study we have described the establishment of 
two syngeneic monoclonal antibodies directed against a permanent 
growing cell line derived from a Rauscher virus (R-MuLV) induced 
murine myeloid leukemia. These monoclonal antibodies proved to 
be specific for virally transformed leukemic cell lines and are 
able to identify a viral antigen with a molecular weight of 
12 x 103 daltons and its precursor proteins. 
In this study we report the labelling of one of these 
monoclonal antibodies with 125I and its injection in tumor 
bearing mice to detect these tumors by scanning. The specific 
binding was analysed quantitatively in these mice by measuring 
the radioactivity in the tumor and various organs. In a second 
experiment the specific localization of 125I-labelled monoclonal 
antibodies was demonstrated in mice bearing solid and 
disseminated tumors by autoradiography. 
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~ice_ang_tu~ors 
Male and female BALB/c mice, 6 weeks old were obtained from 
TNO Zeist (The Netherlands) and kept under routine conditions. 
Subcutaneous tumors were induced after injection of 107 myeloid 
leukemic cells (RMB-1) which were induced by Rauscher Murine 
leukemia virus (R-MuLV) and which grow permanently tu_vtvo and iu 
YitrQ (10,11). Animals with disseminated tumor foci in lungs and 
hemopoietic organs were obtained three days after intravenous 
(i.v.) injection of 107 RMB-1 cells. 
~onocloual autibodies 
In this study two monoclonal antibodies i.e. IC5F5 and 4D2B4 
were used of the IgG2a and IgG2b subclass, which are specific for 
RMB-1 cells. Details concerning the generation and purification 
have been described previously (5a). As control IgG2a was used, 
isolated from ascites fluid of BALB/c mice bearing the hybridoma 
4E3, which does not bind to RMB-1 cells. 
Iodiuation Qf_antigodies 
A. Iodination of monoclonal antibody with 131 I was carried 
out according to a modification of the method described by 
McFarlane (26). Purified monoclonal antibodies (3 mg) in 50 ~1 of 
PBS were added to 15 ~1 of 1 M glycine/NaOH pH10. 25 ~1 of 1 M 
glycine/NaOH (pH10) were added to 25 ~1 of Na131 I (1 mCi) 
dissolved in dilute NaOH (Amersham, Int. Bucks, U.K.). To this 
solution 10 ~1 of 10 mM cold ICl in PBS were added and 
immediately mixed with monoclonal antibody solution. After 5 min 
incubation at room temperature the reaction was stopped by 
separating monoclonal antibody and free Na131 I on a Sephadex G50 
(Pharmacia, Uppsala, Sweden) column in PBS. The fractions 
containing the iodinated monoclonal antibodies were pooled, and 
stored at 4°C. The specific activity was determined by measuring 
the radioactivity and protein content and was 0.6 mCi/mg. The 
binding of the antibody was determined under saturating 
conditions. Briefly, target and control cells were coated on 
microtiter well trays (Nunc, Denmark) and incubated with labelled 
antibody diluted in PBS + 2% BSA. The wells were thoroughly 
92 
washed, trays were cut out with a hot scalpel and counted 
separately in a LKB gammacounter. The binding ranged from 10% to 
40% of the amount of added radioactivity. 
B. 125I-labelled monoclonal antibodies were prepared 
according to Bolton and Hunter (7). The 125I-Bolton-Hunter 
reagent (1 mCi sp./act. 2200Ci/mol) was purchased from Amersham, 
U.K. After evaporating to dryness under nitrogen at room 
temperature, 100 ~g of purified monoclonal antibody in 0.1 M Na 
phosphate buffer pH 7.4 was incubated with the reagent for four 
hours on ice. The unbound 125 I was removed by gelfiltration on 
a Sepharose G50 column. Purity of the labelled antibody was 
checked by polyacrylamide gel electrophoresis followed by 
autoradiography according to Laemli (22). The specific activity 
of the labelled monoclonal antibodies ranged from 
1.5 - 2.2 ~Ci/~g protein. The binding of the labelled antibody 
was determined as described before. It was 40-50% for 4D2B4 and 
45-67% for IC5F5. 
Cle~r~nce of injected autibogies_from the p~riphera~-~~QQg 
Amounts varying from 1.5 to 15 ~Ci 125 I-labelled monoclonal 
antibody IC5F5, 4D2B4 or 4E3 in PBS were injected in the lateral 
tail vein of healthy and tumor bearing mice. Two drops of Lugols 
solution were added to 100 ml of drinking water to inhibit 
thyroid uptake of radioactive iodine. At various times after 
injection the radioactivity was measured in 1 ~1 serum collected 
from the orbital plexus. The binding of the isotope to circu-
lating immunoglobulins was again verified by gel electrophoresis 
followed by autoradiography. 
~cauuing 
Tumor bearing mice were given a single i.v. injection of 
150-200 ~Ci 131 I-IC5F5 or 131I-4E3 and scintigraphy was carried 
out 3-7 days later using a gamma scintillation camera with a 
pinhole collimator (PhoGamma III HP, Siemens, Gamma-sonics). For 
imaging mice were anaesthesized by intraperitoneal injection of 
0.2 ml Hypnorm (Duphar) 1:4 diluted in PBS and put in the prone 
position. The data were collected in a dedicated computer 
system. Images were obtained in a 64 x 64 wordmatrix from the 
131I peak (364 KeV) at the third, fifth and seventh day. 
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Quantitstiy~ aoslysis of the snttbody distr19utton 
After the final scintigraphy all mice scanned were killed 
and the tumor and selected organs were excised dried and weighed. 
The radioactivity of each organ was measured in a gamma counter. 
Results were expressed as counts per minute (cpm) per milligram 
of dried tissue. Ratios of the radioactivity content of tumor 
and different organs to muscle tissue were determined since the 
latter can be used as a well vascularized control tissue. In 
addition ratios of tumor tissues to blood were determined, which 
allows comparison with other studies. To control aspecific 
distribution also 131r-labelled 4E3 was injected. This antibody 
does not bind to RMB-1 tumor cells in vitro. The results are 
expressed graphically. 
The specific distribution was corrected for aspecific accumu-
lation of labelled monoclonal antibodies in tumor tissue by 
calculating the localization index (LI) according to Moshakis et 
al. (28). 
counts/mg tumor IC5F5 counts/mg muscle 4E3 
LI = 
----------------------- X ---------------------
counts/mg muscle IC5F5 counts/mg tumor 4E3 
~utoradiogrsphy 
Cytopreparations of RMB-1 cells were first incubated in yitrQ 
with 1 ~Ci 125I-labelled monoclonal antibody and analysed 
autoradiographically to verify binding. Animals were injected 
with 15 ~Ci (10 ~g) 125r-IC5F5 which were inoculated intra-
venously with 107 RMB-1 cells three days before or subcutaneously 
2 weeks earlier. As control 25 ~Ci (12 ~g) 125I-4E3 was 
injected. Seventy-two hours after injection mice were killed by 
cervical dislocation. Tumors and selected organs were removed, 
fixed in 10% buffered formaline and embedded in paraffin. 
Sections were cut, dewaxed and dipped at 45°C in a Kodak NTB2 or 
Ilford G5 photo-emulsion 1:1 diluted with distilled water. They 
were exposed in light-tight boxes at 4°C for 2-8 weeks. After 
development the sections were counterstained with hematoxylin-
eosine. 
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Sections of paraffin blocks were used both for 
autoradiography and for immunohistochemical staining using a two 
steps immunoperoxidase staining with goat anti-mouse IgG labelled 
with horseradish peroxidase. Sections were also treated with 
reticulin and elastic tissue stains for detection of blood 
vessels. 
:BESULTS 
Scanntng aud in vivQ_distributtgn 
Optimal imaging of tumors in IC5F5 treated mice was obtained 
5-7 days after injection of 200 ~Ci 131I-labelled antibody as 
shown in Figure 1. 
Fig. 1. Radioscintigrapy of 
tumor bearing mouse 7 days after 
i.v. injection of 200 f:LCi of 
13lr-labelled ICSFS. The tumor 
is localized subcutaneously at 
the right site. Contours of the 
mouse are marked with a radioac-
tive cobalt pen. 
In the control group treated with 200 ~Ci 131I-4E3, which does 
not bind to RMB-1 cells, no accumulation in tumor tissue was 
observed. Two mice in this group, bearing large, partly necrotic 
tumors (weight 2-2.5 gr) also had imaging of their tumors, but in 
these cases, equivalent activity was also present in the upper 
abdominal region. 
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After scanning the animals were killed and selected organs 
and tumors were excised, weighed after drying and radioactivity 
was measured. The average fraction of injected labelled specific 
monoclonal antibodies recovered from 1 gram tumor tissue was 
10.6% after 7 days. For non-specific antibodies this fraction 
was 2.9%. The results of the measurements of radioactivity 
expressed as ratios of specific activity in tumor and some other 
organs to nonspecific activity in muscle are shown in Figure 2. 
In all tumor bearing animals treated with labelled specific 
antibodies the accumulation was greater in tumors than in other 
tissues resulting in higher tumor to muscle ratios. However, 
kidney and heart tissue also accumulate considerable amounts. In 
most tumor bearing animals treated with non-specific antibodies, 
the accumulation in tumor tissue was greater than in other organs 
in only 1 of the 5 animals. 
The LI calculated according to Moshakis et al. (28) was 4.44, 
when tumor and muscle tissue are compared, whereas it was 1.83 in 
the comparison of kidney to muscle and 0.99 in case of spleen to 
muscle. Since the tumor consists of leukemic cells, the 
spleen/muscle ratio was used as reference. This implies that the 
LI for tumor tissue was 4.5 times greater than for spleen cells. 
Specific binding of IC5F5 antibody to tumor was therefore evident 
in contrast to the binding of non-specific 131 I-IgG2a. When 
tumor to blood ratios were determined an average of 5.6 was 
obtained for tumor bearing mice injected with 131 I-labeled IC5F5 
and a ratio of 0.48 for tumor bearing mice treated with 131r-4E3. 
Calculation of the labelling index showed a corrected value of 
11.7, which is two times higher than for tumor to muscle ratios. 
Clearauce 
Mice with extended disseminated tumors and control mice were 
given 15 ~Ci (10 ~g) 125 I-IC5F5, 24 ~Ci 125 r-4D2B4 (11 ~g) or 
15 ~Ci (7 ~g) 125I-4E3. Simultaneously, mice bearing subcuta-
neous tumors were given 15 ~Ci 125I-IC5F5. 
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Fig. 2. Ratios of amount of radioactivity of different organs and tumor 
tissues taken 7 days after i.v. injection of 200 ~Ci 1311 ICSFS. For compari-
son tumor bearing mice are injected with 200 p.ci 13 1r-labelled 4E3. 
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Table 1 Percentage of residual serum radioactivity one hour 
after injection. 
Antibody Mice with Mice with Control mice 
subcutaneous disseminated 
tumors tumors 
% % % 
125I-IC5F5 (15 ~Ci) 38.8 I 4.7 26.2 I 7.0 41.0 I 5.9 125I-4D2B4 (24 ~Ci) n.t. 20.7 + 6.6 36.2 I 4.9 
125I-4E3 
~ 
(15 ~Ci) n.t. 49.8 I 1.3 56.5 I 6.1 
As shown in table 1 both specific monoclonal antibodies IC5F5 and 
4D2B4 had a rapid decline of serum radioactivity in the first 
hour after injection in mice having disseminated tumors, which 
was faster than in control mice. This more rapid clearance 
continued in the following 24 hours (Fig. 3a and b). With 
control antibody 4E3 clearance was also rapid, but no striking 
differences were observed between the two groups (Fig. 3c). When 
animals bearing subcutaneous tumors were compared with control 
mice, a difference in initial clearance was less obvious 
(table 1, Fig. 3a). Equal patterns were seen using lower doses 
until 1.5 ~Ci (1 ~g) IC5F5 (data not shown). 
~utoragiograpby 
RMB-1 cells incubated with ~Ci 125I-IC5F5 in vitro had 
specific affinity in the autoradiograms. Normal thymocytes did 
not bind IC5F5 (not shown). In_viyg targeting to RMB-1 cells was 
carried out in tumor bearing mice after i.v. injection of 15 ~Ci 
125I-labelled antibodies followed by autoradiographic analysis. 
Figure 4 demonstrates foci of labelled RMB-1 tumor cells in the 
liver (a), spleen (b) and lung {c) of mice after i.v. injection 
with 125 I-IC5F5. Irregular foci of tumor cells were found 
throughout the liver parenchyma and small clusters of RMB-1 cells 
were detected underneath the spleen capsule. Single cells or 
very small clusters were seen in the capillaries of the alveolar 
septae of the lung. On all these spots high grain densities were 
present in the autoradiograms, whereas few grains were seen in 
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adjacent tissues. High grain densities were also seen in the 
periphery of several lymphfollicles in the spleen (not shown). 
Animals treated with 125I-4D2B4 had a similar grain 
distribution, but with less contrast. In these autoradiograms the 
tumor mass in the hemopoietic organs was more extensive. 
However, in spite of the presence of grains in surrounding well-
vascularized areas, most grains were localized in tumor islands. 
A striking accumulation was seen in the periphery of lymph 
follicles of the spleen as noted for IC5F5. 
In contrast to both monoclonal antibodies, the distribution 
of the non-specific 125I-IgG2a was random throughout the differ-
ent organs and is restricted predominantly to the vasculature. 
High grain densities were particularly found in liver sinusoids 
(Fig. 4e) and vascular beds of lung and kidney. No specific 
binding to tumor cells was noted. 
Histological examination of subcutaneous tumors of animals 
injected with 125I-IC5F5 (Fig. 4d) showed high grain densities 
particularly in the well-vascularized peripheral parts of the 
tumor. Also tumor parts with intercellular edema had grains in a 
narrow zone around the cells, whereas, in compact areas, only 
minimal grain deposition was observed. Staining of elastic and 
reticulin fibers showed that vascularization in these areas was 
poor. 
The identity of RMB-1 cells was confirmed by immunoperoxidase 
staining using the same monoclonal antibodies. Control sections 
of mice treated with non-specific IgG2a did not stain these tumor 
cells. 
QISCUSSlQ~ 
The radioimmune detection of a tumor is dependent on several 
factors i.e. 1) The specificity of the antigens to which the 
antibodies are directed and their concentration on individual 
tumor cells. 2) The efficiency of the labelling procedure and the 
specific biological activity of the labelled antibody. 3) The 
route of administration by which the labelled antibodies reach 
the tumor cells and 4) A sufficient clearance of unbound labelled 
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Fig. 4. Autoradiography of RMB-1 metastases in liver (a), spleen (b), lung 
(c), and of subcutaneous RMB-1 tumor (d) 3 days after injection of 15 J.I.Ci 
12 5r-labelled IC5F5. Liver with disseminated tumor cells of mouse injected 
with 125r-labelled control antibody 4E3 (e). magn. 380x 
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antibodies to ensure detection of specifically bound antibodies. 
Each of these factors is discussed below. 
Jte~-1~ There is scepticism about the existence of tumor specific 
antigens and most authors consider these antigens at least in 
human cancers as onco-foetal antigens (15) such as the CEA and 
a-fetoprotein (19). However, in virally transformed cells, they 
may be related to viral proteins, to viral encoded or induced 
transforming proteins (35). In that sense these antigens may be 
considered as tumor specific. 
The monoclonal antibodies used in this study as seen with 
ELISA and Western blotting techniques reacted extensively with 
Rauscher virus-induced myeloid leukemic cells and bond to the 
viral proteins expressed on these cells, but did not react with 
uninfected control cells (5a). This ensures specific detection 
of leukemic cells, injected in non-infected animals. 
It~~-~~ The purification and labelling methods used did result in 
an electrophoretically pure antibody with a specific activity of 
2.2 ~Ci/~g and a binding activity up to 67% of the labelled 
antibody added. 
Jte~-3~ In this study it has been shown that iu_viyQ injected 
myeloid leukemic cells home in several organs with a preference 
for hemopoietic organs. Histologically, foci of tumor cells can 
be easily detected in the normal tissues, often displaying an 
intimate relationship to the vasculature. The i.v. 
administration of labelled antibodies, therefore, ensures ready 
accessibility to tumor cells. 
Jte~-~- Clearance of labelled antibodies from the peripheral 
blood is dependent on metabolic degradation, excretion mechanisms 
and the binding to tumor cells (31). In this study a rapid 
clearance differential was found in mice with disseminated tumors 
as compared to controls, whereas less difference was obtained for 
animals bearing subcutaneous tumors. 
Successful! imaging of s.c. tumors was possible from the 5th 
day after injection of labelled antibodies. The lowest back-
ground was observed on day seven, which is in accordance with the 
clearance curves and radioactivity measurements of the tumor and 
in other tissues. 
102 
Such retarded but specific accumulation has also been repor-
ted after scanning of a number of solid tumor bearing (nude) mice 
treated with monoclonal antibodies against an oncofetal marker 
such as CEA (9,30), melanoma-specific antigen (18), antibody 
directed to a mouse teratocarcinoma (23) or with antibodies 
recognizing a hepatocarcinoma-related antigen in guinea pigs (6). 
These results are in contrast to those of Scheinberg and Strand 
(33) using monoclonal antibodies directed against the viral 
glycoprotein gp70 detecting leukemic spleen cells and to data of 
Shah (34), who used antibodies which recognized human breast and 
colon tumor cells which were grafted directly into spleens. They 
reported excellent images within 24 hours after injection. This 
discrepancy may be due to the greater accessibility of these 
tumor cells within highly vascularized organs. This might also 
explain the controversial results concerning the plasma clear-
ances in animals bearing subcutaneous tumors (27) and in animals 
with splenic tumor cells (31). This is supported by the studies 
of Sands et al. (32) who measured the blood flow in identical 
tumors localized either s.c. or under the renal capsule. 
The positive imaging of tumors treated with non-specific 
labelled monoclonal antibody may be explained by the nonspecific 
accumulations in the intercellular space as described by Bale 
(2). This mechanism is probably less important in highly 
vascularized or small tumors with a relatively small extra-
vascular space. The specific accumulations of tumor specific 
monoclonal antibodies is corrected by the nonspecific distribu-
tion of monoclonal antibodies (4,28). In this study this correct-
ion results in a 4.5 fold higher LI value for tumor cells as 
compared to spleen 
blood is compared. 
cells and a 11.7 value when tumor tissue to 
Literature data show that the fraction of 
labelled monoclonal antibody recovered and the tumor to blood and 
tumor to muscle ratios are dependent on the amount of radioacti-
vity injected, the type of monoclonal antibody and the time of 
measurement. Our tumor to blood ratios lie in the same range as 
those of Fand et al. (13) and are about two times higher than 
those of Ballou et al. (3), Midoux et al. (27) and Buchegger et 
al. (9), but are much lower than the ratios reported by Bernhard 
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et al. (6). In contrast with these results Pimm et al. (13) have 
reported tumor to blood ratios smaller than 1.0. However, in the 
studies mentioned other correction methods were applied for 
nonspecific binding. Others have applied subtraction methods for 
correction of nonspecific binding using two different isotopes, 
one of which is bound to a nonspecific antibody (3,14). 
To ensure a rapid clearance and to prevent Fe binding, some 
authors have used F(ab)2 fragments instead of whole antibodies 
(9,16,25). Although this method gives lesser background, doubts 
exist about its efficiency (8). In this study we used intact 
antibodies which also gave satisfactory results. 
Autoradiographic techniques in s.c. tumors and lymph node 
metastases have also been carried out by several authors 
(24,29,30,32) as well as immunoperoxidase techniques (12,20). 
Nearly all authors found preferential localization in the 
periphery of tumors which usually is the most vascular. Our 
results confirm this. In the visceral tumors, however, grain 
density was inversely related to increasing tumor diameter. This 
may be explained by excess of antigen and concomittant depletion 
of labelled antibodies or by a lower penetration of these 
antibodies. 
In contrast to the use of allogeneic monoclonal antibodies, 
the use of syngeneic monoclonal antibodies in specific targeting 
by pure syngeneic monoclonal antibodies made from spleens of 
tumor bearing animals has only rarely been described (17). This 
is due to the fact that not all tumors evoke an host immune 
response. The value of syngeneic antibodies lies therefore in 
their tumor specificity. This allows detection of metastases and 
circumvents an anti-antibody response in repeatedly treated 
animals (5b). Such a system is an excellent model for further 
exploration of the basic mechanisms in monoclonal antibody 
immunotherapy. 
We thank Dr. A. Dekker for critical reading the manuscript. 
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A syngeneic monoclonal antibody (MAb)(IC5F5) was successfully 
used in the immunotherapy of Rauscher virus-induced myeloid 
leukemic RMB-1 cei'ls. It is directed to a virus encoded, but 
aberrantly processed protein, which is expressed on the cell 
membrane. When applied in_yiyQ, it binds only to RMB-1 tumor 
cells. BALB/c mice were inoculated i.p. or i.v. with 10 7 RMB-1 
cells and died within 2-3 weeks due to increasing tumor load. 
Mice inoculated i.p. were completely cured by daily injections of 
ascites containing IC5F5. Disseminated tumor cells in liver and 
hemopoietic organs were observed after i.v. inoculation. Daily 
treatment with MAbs resulted in survival beyond 90 days. No 
antigenic modulation was observed when tumor tissue was analysed 
2-10 days after treatment. Treatment was successful even when 
therapy was postponed until day 5 following inoculation of tumor 
cells. When the number of ascites injections was reduced, 
survival was identical to that observed among repeatedly treated 
mice. Ten- and 100-fold dilution of ascites fluid diminished the 
number of survivors, but still resulted in a median survival time 
of 38 and 20 days, respectively, as compared to 14 days for 
untreated mice. 
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Immunotherapy using conventional polyclonal antibodies has 
been successful in virally induced murine leukemias (Schafer 
et al., 1976; Collins et al., 1978) as well as in some xenograf-
ted human neoplasms (Rosenberg and Terry, 1977). The introduction 
of MAbs (Kphler and Milstein, 1975) has greatly increased inter-
est in possible serotherapy of malignant tumors. For instance, 
in murine models, inhibition of tumor growth has been shown to 
occur with allogeneic MAbs in primary leukemias as well as in 
grafted leukemic cells (Bernstein et al., 1980; Kirch 
and Hammerling, 1981; Scheinberg and Strand, 1982; Badger et 
al., 1986). Human tumors transplanted into nude mice have also 
been successfully treated in this way (Koprowski et al., 1978; 
Herlyn et al., 1985). 
Pure syngeneic MAbs have only occasionally been used for such 
treatment. These were obtained as fusion products of spleen 
cells from immunized animals with myeloma cells bearing the same 
genotype (Herlyn et al., 1980; Kennel et al., 1983, 1985). 
Two syngeneic MAbs have been characterized, which are 
directed to Rauscher virus-transformed myeloid leukemic cells 
(Berends et al., 1988a). Both bind to viral proteins localized 
in the cell membrane. Binding to tumor cells to ytyo has been 
evidenced by 125I-labelling and autoradiography. 
We now report the therapeutic effects of MAb IC5F5, using 
different experimental conditions. This MAb is of the IgG2a 
subclass. Most previous experimental studies have used one 
single focus (usually s.c. tumor) in order to test the results of 
treatment. In contrast, our work studies the effect of 
immunotherapy on disseminated tumors and as such it more 
accurately reflects metastasized cancers, which are usually 
difficult to cure. 
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Cell_l~oe 
We have used the myeloid cell line RMB-1, which is induced by 
Rauscher virus to grow permanently io_yit~Q and in viyQ (De Both 
et al., 1981; Delwel et al., 1987). Cells were cultured in 
RPMI 1640 + 10% fetal calf serum (Seromed, Miles, Brussels) 
~~ge_aog tYIDQr 
Male and female BALB/c mice, 
from TNO, Zeist (The Netherlands). 
ted tumors were obtained by i.p. 
8-12 weeks old, were obtained 
Intra-abdominal and dissemina-
or i.v injection of 107 RMB-1 
cells. 
Moooclonal_aotibogy 
Ascites fluid containing MAb IC5F5 was obtained after 
injection of 15 x 106 hybridoma cells i.p. in BALB/c mice pre-
treated 10-21 days earlier with 0.5 ml Pristane (Janssen, Beerse, 
Belgium). Ascites fluid of mice bearing the non-binding 
hybridoma 4E3 was used as control. 
Io yit~Q modulation 
RMB-1 cells were co-cultured with or without 1% IC5F5 or 4E3 
ascites. After 2 days the 
in culture medium with 
cultured cells was counted 
cultures were centrifuged and re-fed 
or without ascites. The number of 
daily. Some cultures were measured 
for expression of the IC5F5 antigen by flow cytometry, while 
others were incubated for 2 more days and then measured for 
antigen expression. Flow cytometric measurement of IC5F5 antigen 
expression was carried out as follows: 10 6 cultured RMB-1 cells 
were washed twice with Hanks' balanced salt solution (HBSS) 
containing 5% FCS and 0.02% sodium azide. They were then 
incubated for 45 min on ice in 50 ~1 IC5F5 or 4E3 ascites, both 
diluted 1:1,000 in HBSS. The cells were again washed with HBSS, 
then labelled for 30 min with goat anti-mouse IgG2a/fluorescein 
isothiocyanate (GAM/FITC; Nordic, Tilburg, The Netherlands), 
diluted 1:50 in HBSS. After washing, the cells were resuspended 
and analyzed for IC5F5 antigen expression using a fluorescence 
activated cell sorter (FACS II, Becton Dickinson, Sunnyvale, CA). 
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In_yiyg_mod~latign 
Tumor bearing BALB/c mice were treated with IC5F5 or with 4E3 
ascites fluid as control, and killed 2, 4 and 10 days after the 
beginning of treatment. Organs were excised and frozen sections 
were either pre-incubated with IC5F5 or 4E3 ascites (1:1,000), 
followed by incubation with goat anti-mouse IgG labelled with 
peroxidase (GAM/PO), or stained directly with GAM/PO, to detect 
residual previously injected mouse MAbs. 
Tberapy e~perimeots 
In order to determine the dose of RMB-1 cells needed to kill 
50% of the mice (LD 50), animal survival was determined after 
i.v. inoculation of 10 5 -2.10 7 RMB-1 cells into groups of 9 mice 
each. Animals were monitored daily to score their mortality. 
Trestmeot gf intra-peritonea~ __ sog __ g~~~e~~osteg_t~~Q~~ 
Mice were inoculated with 10 7 RMB-1 cells either i.p. or i.v. 
Immunotherapy was started with 0.1 - 0.2 ml ascites containing 
MAb IC5F5, to which 0.05 ml fresh normal rabbit serum was added. 
The antibody titer in different ascites batches was tested using 
an enzyme-linked immunosorbent assay (ELISA). Batches exhibiting 
comparable activity were mixed together to obtain equivalent 
preparations. Typical preparations had a protein content of 
about 50 mg/ml, which is equivalent to 2 mg Sepharose 
protein A-purified MAb. This produces an extinction of the 
positive signal in an ELISA at a dilution of 10-5 • Control 
animals received phosphate buffered saline (PBS) or ascites of 
BALB/c mice inoculated i.p. with the non-binding hybridoma 4E3. 
Animals were monitored daily for mortality. The results are 
expressed graphically as percentage of survivors against time. 
The median (MST) as well as the average survival time I the 
standard deviation (SD) were scored. 
In order to determine the extent of tumor growth, mice were 
killed after different periods of time without treatment and 
their tissues were embedded for histological examination. 
Statist~g§l 
Survival curves of treated and untreated groups as observed 
on the 60th day were tested for similarity by Breslow's version 
of the Wilcoxon test, using program 1L of the BMDP statistical 
113 
software package (Dixon, 1983). The statistics tested correspond 
to a chi-square distributed variable with 1 degree of freedom. A 
probability of 1% or less (P < 0.01) between 2 survival curves 
was considered as significantly different. 
GAM IgG2a - FITC IC5F5 + GAM IgG2a - FITC 
4E3 
"' ..... c: 
"' > 
"' .J 
..... 
0 
L. 
"' .0 E 
=> 
c: 
IC5F5 
Fluorescence IntensitY <arbitrary units> 
Fig. 1. Fluorescence of RMB-1 cells cultured for 2 days with or without IC5F5 
ascites. Fluorescence is expressed logarithmically. 
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~bseuce_of_iu_vtt~o-~utigeutc_~ogylattoo 
Antigenic modulation may influence the results of 
immunotherapy. We thus tested the possible occurrence of 
antigenic modulation to Yit~o. After culture of RMB-1 cells for 
different periods with a saturating amount of IC5F5 ascites, the 
presence of antibody and antigens was tested by indirect 
immunofluorescence using a FACS. Figure 1 shows that the 
presence of the specific antigen remained unaltered during the 
whole incubation period and that it was not influenced by the 
presence of antibody. After 2 and 4 days similar results were 
obtained. This indicates that shedding of the IC5F5 antigen does 
not occur. No difference in the number of cells was observed 
between cultures with and without antibody, indicating that 
proliferation was not inhibited. 
The~apy 
~. Tre~t~eut_of_tut~~pe~itoneal_tu~or~ 
To evaluate immunotherapeutic effects of IC5F5 a series of 
experiments was made using mice inoculated i.p. with 107 RMB-1 
cells 24 hr earlier. This dose kills mice within about 3 weeks. 
Mice inoculated with RMB-1 cells were treated i.p. with 0.1 ml 
IC5F5 ascites daily for 14 days. One group of animals was 
treated with 0.1 ml IC5F5 ascites and 0.05 ml fresh rabbit serum 
to verify whether therapy is improved by complement (Bernstein et 
al., 1980). Figure 2 shows survival after 20 days. All control 
mice treated with 0.1 ml PBS plus 0.05 ml rabbit serum died 
rapidly within this period, whereas 80-100% of the animals 
received no rabbit serum remained alive. The final results 
obtained with and without addition of complement were similar, so 
complement was omitted from further experiments. 
B. Tre~t~eut_of_gl~~e~lnate9 tY~Q~s 
Since fatal intraperitoneal i.p. tumor growth was abolished 
by treatment with specific MAbs, the effect of this treatment was 
also investigated in mice inoculated i.v. with RMB-1 cells. 
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Fig. 2. Percentage of survival 20 days after i.p. inoculation of 10 7 RMB-1 
cells. (mDDDDl Mice treated i.p. with 0.1 ml ICSFS ascites; or (~) 0.1 ml 
ascites + 0.05 ml normal rabbit serum; or ( ..... ) 0.1 ml PBS + 0.05 ml normal 
rabbit serum. Therapy was started 24 hr after tumor cell inoculation. n = 10. 
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Fig. 3. Survival of mice injected i.v. with different numbers of tumor 
cells (plotted logarithmically). Each point represents 9 mice. Short horizon-
tal bar indicates LD 50. 
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These leukemic cells home initially to the liver, spleen and bone 
marrow and thereafter to other organs, resulting in disseminated 
cancer, which rapidly kills the animal. Because this situation 
resembles metastatic tumor growth, we decided to use it as a 
model to test the immunotherapy. 
First the dose capable of killing 50% of the mice (LD 50) was 
determined (Fig. 3). Fifty percent of the animals died after 
i.v. inoculation of 2-3 x 105 RMB-1 cells. Inoculation of 107 
cells resulted in 100% death within 15-20 days. 
However, when treated with daily injections of IC5F5 starting 
24 hr after inoculation, mice showed prolonged survival. Mice 
treated with ascites fluid of the non-binding antibody 4E3 all 
died within 20 days (data not shown). 
To ensure outgrowth of inoculated RMB-1 cells to micro-
metastases in the organs in another series of experiments we 
waited at least 3 days before starting the IC5F5 treatment. 
C~ _Yari?tiou_in tit~r_of_?uti9o9i~~ appli~g 
Groups of 20 mice were treated daily i.v. for 10 days with 
undiluted IC5F5 ascites or with various dilutions (Fig. 4a). 
After injection of undiluted IC5F5 ascites, 70 % of the animals 
were cured (survival for over 90 days). Injection of a 10-fold 
dilution resulted in 45% cure (MST 38 days). A 100-fold dilution 
still resulted in a higher median survival time (MST 20 days) 
than that of control animals (MST 10 days). A 1,000-fold dilu-
tion, however, did not significantly alter long-term survival. 
Statistical analysis of survival curves of the various experi-
mental groups compared with the survival curve of control mice 
revealed significant differences (P < 0.01). The median and 
average survival times, as well as the various p values are 
presented in Table I. 
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Table I Effect of antibody dose on host survival* 
Antibody Dilution Number of Median Average P value 
survivors/ survival survival treated/ 
total number time time 
.!. SD control 
of mice (MST) 
j 
IC5F5 undiluted (14/20) - 70"/o 60 53.3 .!. 3.2 p < 1 o- 4 
IC5F5 1: 10 ( 9/20) - 45"/o 38 38.8.!. 5 p < 1 o- 4 
IC5F5 1:100 ( 3/20) - 15"/o 20 24.9 + 3.5 
..... 
p < 10-4 
IC5F5 1:1000 0/20) - 0"/o 14 14.2.!. 0.3 p < 3.10-4 
4E3 undiluted 0/20) 0"/o 10 11.3.!. 0.4 
--------------~-------------------------------------------------------
* measured up to 60 days after inoculation of tumor cells 
~- _PQstpQgeg treat~ent 
Since prolonged survival was obtained when treatment was 
started at least 72 hr after inoculation, the therapy-free 
interval was extended to 5 or 7 days. The results are shown in 
Figure 4b. Survival after a 5-day interval was similar to that 
observed after a 3-day interval as shown in Figure 4a. However, 
a 7-day delay resulted in death of all treated mice. Figure 5 
shows a representative example of tumor growth in the liver of 
untreated mice at day 5 after inoculation. Tumor foci were also 
found in the spleen and bone marrow and, to a lesser extent, in 
the lungs. 
E~ __ Single_ver$ys_rePe?ted_gose$ 
To compare the effect of a single injection of 0.2 ml 
undiluted IC5F5 ascites with that of repeated administration, 
groups of mice inoculated with 10 7 cells i.v. were treated, 
starting 72 hr later either once or 4 times at intervals of 
4 days. Control mice received 4 injections of 0.2 ml non-binding 
4E3 ascites. As shown in Figure 4c the survival is nearly 
identical in the 2 groups treated with specific MAb and is 
comparable to the results of daily treatment with undiluted IC5F5 
ascites, as shown in Figure 4a. Obviously, high initial antibody 
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Fig. 4a. Survival of mice inoculated i.v. with 10 7 RMB-1 cells after treatment 
with 0.2 ml IC5F5 ascites, or with 4E3 ascites as control. Daily treatment 
with various dilutions of IC5F5. T = start of treatment. 
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Fig. 4b. See legend to figure 4a; start of treatment postponed until day 5 
(Tl, n = 9) or day 7 (T2, n = 10) after inoculation. 
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Fig. 4c. See legend to figure 4a; comparison of 4 injections at 4 day inter-
vals with one single injection (n = 10). 
levels are of the utmost importance for successful immunotherapy 
in this disseminated tumor model. 
~P§ence of iP_YiY9 wggu~atigo 
Modulation of the antigen recognized by IC5F5 does not take 
place ip_yitro. To exclude possible interference with treatment, 
modulation was also studied io_yiyg. Frozen sections made of 
livers of tumor bearing mice treated for 2, 4 and 10 days by 
daily i.v. injections of 0.2 ml IC5F5 or 4E3, were directly 
stained with GAM/PO. Other sections of the same liver were pre-
incubated with IC5F5 ascites before incubation with GAM/PO. In 
Figure 6a a focus of tumor cells can be seen in the liver of a 
mouse treated with IC5F5 for 48 hr. The section is stained with 
GAM/PO only. The presence of antibody is shown by positive 
staining of the periphery of the tumor. Upon pre-incubation with 
MAb all the cells are stained (Fig. 6b). These data indicate 
that the target antigen detected by IC5F5 persists on the tumor, 
but that in larger foci i.v. injected antibody binds 
predominantly to the periphery of the tumor tissue. Sections of 
organs of mice treated with 4E3 did not show any staining after 
incubation with GAM/PO. 
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Fig. 5. Extent of tumor 
growth in liver 5 days 
after tumor cell inocu-
lation. 
Fig. 6. Peroxidase stai-
ning of serial frozen 
sections of liver contai-
ning disseminated tu-
mors, treated twice with 
IC5F5 ascites. (a) stai-
ning with GAM/PO; (b) 
pre-incubation with IC5F5 
followed by staining 
with GAM/PO. 
a 
b 
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DISCUSSION 
Previous studies have demonstrated that the efficacy of 
cancer immunotherapy is influenced by a number of factors. One of 
the most important of these is the specificity of the antigens to 
which the (monoclonal) antibodies are directed. In the case of 
human tumors, antibodies against the oncofetal antigens CEA in 
colorectal carcinomas (Herlyn et al., 1980) or against the 
idiotype of B cell lymphomas (Miller et al., 1982) are suffi-
ciently specific to allow immunotherapy to be used. 
In animal models treatment often comprises antibodies which 
are directed to differentiation antigens, such as Thy-1.1, 
expressed on T cell lymphomas (Bernstein et al., 1980, Badger and 
Bernstein, 1983), or to tumor-associated glycosylated antigens 
which are not present on normal cells (North and Dean, 1983). 
The RMB-1 cells used in this study express viral proteins which 
can be considered as highly tumor-specific. 
The density of the antigens seems equally important, since 
variants having a smaller amount of antigen are more difficult to 
treat (Herlyn et al., 1985). Other major drawbacks of immunothe-
rapy are that selection of antigen-deficient populations may take 
place in tumor cells (Young and Hakomori, 1981) and that antigen 
modulation may occur (Old and Stockert, 1977; Schroff et al., 
1984). 
Although only a moderate number of target antigens is distri-
buted on the cells used in our model, as shown by Scatchard 
analysis (Berends et al., 1988a), successful immunotherapy is 
nevertheless possible. No modulation occurs in our cells, either 
in vitro or in yivo. Apparently the viral protein to which IC5F5 
is directed is consistently expressed on RMB-1 cells. Since 
these cells do not produce virus, no abundant circulating 
antigens are present in the serum of tumor-bearing animals which 
might block the injected MAbs. 
The class and subclass of the antibody applied for therapy 
may be important. As pointed out by many authors the IgG2a 
subclass is particularly powerful in mediating the complement 
dependent cytotoxicity and antibody dependent cellular cytotoxi-
122 
city of macrophages and killer cells (Koprowski et al., 1978; 
Steplewski et al., 1983; Adams et al., 1984; Denkers et al., 
1985). This may explain our good results. In a subsequent study 
we will deal with the possible mechanisms underlying the 
efficient therapy reported here. 
Other immunotherapeutic studies show that the number of tumor 
cells destroyed by successful treatment varies considerably. 
This may reflect differences in malignant potential, which 
depends on the take of the tumor cells, their growth properties 
and differences in the immune response of the host. Comparison 
is therefore difficult and must be related to the median survival 
time (MST) and the number of cells necessary to cause tumor 
growth or death in half of the animals (TD 50 or LD 50). 
An estimate of the tumor load made on the basis of a doubling 
time of 18 hr iP vit~o (de Both et al., 1981) on day 5, yields a 
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maximum of 9.7 x 10 RMB-1 cells. This would imply that cures 
can be achieved in animals containing a number of tumor cells 
that is approx. 3,000 times the LD 50. 
A similar result was obtained by Badger and Bernstein (1983) 
with s.c. inoculated SL2 lymphoma cells in AKR/J mice, but in 
their study the therapy was started a few hours after 
inoculation. A cure of s.c. inoculated mice containing 500 times 
more tumor cells than the LD 50 was reported by Kirch and 
Hammerling (1981) in congeneic AKR mice. In these and most other 
studies allogeneic MAbs were used and similar survival was only 
obtained if therapy was started within 24 hr of tumor cell 
inoculation (Bernstein et al., 1980; Young and Hakomori, 1981; 
Denkers et al., 1985). In our study good results were still 
obtained if the therapy was delayed until the disease had 
progressed to between 1/4 and 1/3 of its total duration 
<i 14-21 days). An initial high dose proved sufficient to 
activate the effector mechanisms. Good results were also 
reported by Kennel et al. (1983, 1985) who started treatment of 
virally induced sarcomas with syngeneic MAbs on the fourth day. 
Treatment with allogeneic antibodies may induce an anti-antibody 
response. This has been observed in patients treated with 
xenogeneic mouse MAbs, leading to reduction of therapeutic 
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efficacy (Miller et al., 1983) or to hypersensitivity reactions 
(Dillman et al., 1982). The use of syngeneic MAbs probably 
avoids this problem and our study shows them to be more powerful 
than allogeneic antibodies. 
We have shown in previous studies that the MAb used for 
therapy binds to a tumor-restricted antigen and that, when 
injected iO_YiYQ, it easily reaches the tumor cells (Berends et 
al., 1988b). Since the present study shows efficient therapy with 
a high dose of IgG2a antibodies directed to a non-modulating 
antigen, our model may approach the limits of successful sera-
immunotherapy of disseminated tumor foci. 
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The present study was undertaken to determine the factors, 
which influence antibody mediated cytotoxicity during immuno-
therapy of virally transformed tumor cells. As model a Rauscher 
virus induced myeloid leukemic cell line of BALB/c origin (RMB-1) 
was used, which forms disseminated tumors, when inoculated 
intravenously in BALB/c mice. As previously reported a prolonged 
survival was obtained when tumor-bearing mice were treated to 
YiY9 with a single high dose of a tumor-specific IgG2a monoclonal 
antibody. 
This study shows, that antibody dependent cellular cytotoxi-
city is an important mechanism involved in tumor cell 
destruction. Since to __ yttro studies showed that peritoneal 
macrophages were capable to kill RMB-1 cells in the presence of 
tumor-specific monoclonal antibody and since in the tumors of 
mice treated with monoclonal antibody a high influx of 
macrophages was observed histologically, it is likely that 
macrophages play an important effector role in elimination of 
tumor cells. Successful therapy in C5 complement deficient 
tumor-bearing mice suggests that 
cytotoxicity does not play a major 
complement dependent 
role. In nude (T cell 
deficient) mice the therapeutical effect of tumor-specific IgG2a 
antibody was significantly less than in immunocompetent mice. 
Although infiltration analysis of tumors of treated and 
untreated mice showed equally low numbers of helper T and 
suppressor/cytotoxic T cells, the mortality studies of T cell 
deficient and immunocompetent mice indicate that T cells play a 
substantial, auxillary role during antibody mediated, tumor 
destruction in our model. 
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Different opinions exist about the mechanisms, which are 
responsible for successful immunotherapy using monoclonal anti-
bodies (Moabs). Although some authors favor complement dependent 
cytolysis (CDC) as an important factor when tumors are treated 
with specific Moabs (8,9), most studies emphasize the role of an 
antibody dependent cellular cytotoxicity (ADCC), especially for 
Moabs of the IgG2a subclass (1,23). Macrophages which are able to 
bind antibodies by Fe receptors seem the main candidates for such 
an ADCC in mice (26,28,39). 
Uncertainty exists about the possible role of T cells in 
monoclonal antibody therapy. Whereas some authors assume that T 
cells do not play a major role (18,19), others suppose that these 
cells act synergistically with antibody mediated mechanisms (27). 
In a previous study we used the Rauscher virus transformed 
myeloid leukemic cell line (RMB-1) to induce disseminated tumors 
by intravenous inoculation. Mice with established tumors showed 
prolonged or complete survival after the administration of high 
doses of a tumor-specific Moab of the IgG2a subclass (5). 
The purpose of the present study is to investigate the role 
of cellular and humoral factors involved in the successful 
sere-immunotherapy in this model. 
~~TERIALS ~ND METHODS 
CeH Hne 
The permanently iu_vit~o and iu viyQ growing R-MuLV induced 
myeloid cell line of BALB/c origin RMB-1 was used (11). Cells 
were cultured in RPMI 1640 plus 10% fetal calf serum (Seromed, 
Miles, Brussels) to which penicillium and streptomycin was added. 
~ige 
Male and fe~ale BALB/c, BALB/c nude mice and DBA/2 mice, 8-12 
weeks old, were obtained from TNO, Zeist (The Netherlands) and 
IFFA-Credo, Lyon (France). Disseminated tumors were obtained by 
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intravenous (i.v.) injection of 107 RMB-1 cells in BALB/c mice or 
5 x 107 RMB-1 cells in DBA/2 mice. 
Monoclonal aotibody 
I 
Ascites fluid containing the IgG2a monoclonal antibody IC5F5 
was generated as described (4,5). This IgG2a monoclonal antibody 
is specific for virally induced proteins which are not expressed 
on normal tissues of BALB/c and DBA/2 mice. As control ascites 
fluid of mice bearing the non-binding hybridoma 4E3 was used. 
CompleiDeot dependent_gytoly~!~_{C~C) 
2 x 106 RMB-1 cells were incubated for 2 hours at 4°C with 
increasing dilutions of IC5F5 or 4E3 ascites fluid. After 
45 minutes the cells were washed and fresh normal rabbit serum 
was added as a source of complement (1:10). Incubation was 
carried out for 30 minutes at 37°C. Cells were washed and the 
percentage of viable cells was determined microscopically in a 
trypan blue exclusion test. A hundred cells were counted. In 
every test, cells were incubated either with rabbit serum or with 
monoclonal antibody alone. These controls invariably contained 
less than 5 percent dead cells and are therefore omitted from the 
figure (Figure 1). 
AntibodY dependeot cellula~ _cytotoxtcity_(~DCC) 
Target cell labelling 
RMB-1 cells were labelled in a concentration of 10 6 cells per 
ml with 200 ~Ci Na2 52cro4 (Spec. Act. 10 - 35 mCi/mmol) during 
2 hours at 4°C. 
For long term experiments RMB-1 cells were labelled overnight 
with 5 ~Ci 3H-methyl-thymidine per ml culture fluid (Spec. Act. 
5 mCi/mmol). 
E(fecto~_cells 
Effector cells were isolated from three different groups 
mice ~ BALB/c mice i.v. inoculated with 10 7 RMB-1 cells 4 
before and treated with 0.2 ml ascites fluid containing 
of 
days 
the 
monoclonal antibody IC5F5 1 day before isolation. ~. idem, but 
treated with the non-specific monoclonal antibody 4E3 and 
~ control mice without tumor and without treatment. 
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A,_ ~acrgpl;).~ges 
Macrophages were obtained by flushing the peritoneal cavity 
of three mice of each group with 5 ml Hanks' balanced salt solu-
tion (HBBS) and the number of nucleated cells was determined. 
After washing the cell suspension the cells were cultured in 
96-well plates (Nunc, Denmark) during 3 hours in RPM! at 37°C. By 
washing the wells with culture fluid the non-adherent cells were 
removed and counted. The adherent macrophages formed a monolayer 
on the bottom of the wells. The number adherent cells were 
calculated by subtraction of the number of non-adherent cells 
from the number of cells initially present in the cell 
suspension. 
:e._ Spl~nocyte§ 
Splenocytes were obtained by mincing spleens of three mice, 
filtering the suspension through a nylon gauze and washing them 
thoroughly in PBS to remove cellular debris. Nucleated cells were 
counted in an haemocytometer. 
~§§!~Y 
Target cells in a concentration of 4 x 10 4 cells/150 ~1 per 
well were added to 10 6 effector cells per 100 ~1 medium (T:E 
ratio is 1:25). Part of the wells were treated with 10 ~1 IC5F5 
ascites fluid whereas the other group was treated with medium 
only. 
Short term incubation with 51cr-labelled cells was continued 
3 during 6 hours, whereas long term incubation with methyl- H-
thymidine-labelled cells varied from 24 till 72 hours. After that 
period the trays were centrifuged at 800 rpm and the amount of 
radioactivity of 100 ~1 culture fluid was counted. To determine 
the maximum amount of radioactivity, which can be released from 
the target cells, wells were treated with Triton X-100 (0.1%) as 
lysing agent. As negative control target cells were used, which 
were only treated with Moabs. All experiments were carried out in 
quadruplicate. 
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experimental cpm - spontaneous cpm 
% specific release = ---------------------------------- x 100 
total cpm - spontaneous 
Therapy exp~riments 
BALB/c and BALB/c nu/nu (nude) mice were inoculated with 10 7 
RMB-1 cells and DBA/2 mice with 5 x 10 7 RMB-1 cells. Treatment of 
tumor-bearing BALB/c and nude mice was started on day 3 with a 
single injection of 0.2 ml IC5F5 ascites fluid. Control mice were 
given either no treatment or 0.2 ml non-binding ascites of 
hybridoma 4E3. 
Tumor-bearing DBA/2 mice were daily injected with 0.2 rnl 
IC5F5 control ascites starting 24 hours after inoculation. The 
ascites was incubated for 20 minutes at 56°C to inactivate 
complement. Mortality of the animals was monitored daily and the 
results were expressed graphically as percentage of survival 
against time. Statistical analysis was carried out as described 
(5). 
Hi~tology_and im~~uohistogbemistry 
From a group of tumor-bearing BALB/c mice which had been 
treated with IC5F5 or 4E3 control ascites fluid, 2-4 mice were 
killed respectively 2, 4, 5, 7 and 9 days after start of treat-
ment. Internal organs were excised, frozen in liquid nitrogen or 
fixed in 10% buffered formaline and embedded in paraffin. 
Paraffin sections were coloured with haematoxylin-azophloxin, 
periodic acid Schiff stain or enzymatically stained for non-
specific esterase to detect macrophages. Selected sections were 
used for immunoperoxidase staining using Moab IC5F5 as described 
previously (4). Frozen sections of liver tissue were incubated 
with Moabs which were specific for the T cell helper subset i.e. 
anti-Lyt-1 and anti-L3T4 or with anti-Lyt-2 corresponding to the 
cytotoxic/suppressor T cell subset. Horse-radish peroxidase 
conjugated to rabbit anti-rat IgG (Dakopatts, Denmark; dilution 
1:100) was used as a second step. Antibodies specific for 
macrophages could not be used because of cross-reactivity with 
RMB-1 cells. These Moabs were kindly provided by 
Drs. P.J.M. Leenen, Dept. of Cell Biology, Medical Faculty, 
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Rotterdam. Positive cells in and around tumor foci were 
microscopically scored in a semiquantitative scale from - to +++. 
R6SULTS 
Comple~eot_Depeodeot_Cytoto~icity 
Figure 1 shows the result of a CDC assay. Over 95% of RMB-1 
cells are killed after incubation with IC5F5 ascites (diluted 
100 times) in the presence of rabbit complement. A rapid decline 
of cytotoxicity can be seen at an antibody dilution of 10-3 and 
higher (Figure 1). Without complement no cytolysis of RMB-1 cells 
took place in the presence of Moab. 
percentage 
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Fig. 1. Cytotoxicity of different 
dilutions of IC5F5 ascites (~) 
compared to control 4E3 ascites 
(e---.. ) in the presence of fresh 
normal rabbit serum. 
~otiQQdy gepeodent_cellulgr_cytoto~icity 
When 51cr-labelled RMB-1 cells were incubated with peritoneal 
macrophages or splenocytes of the different groups of mice, the 
release of chromium was similar during short term incubation 
(till 6-8 hours), with and without antibody and did not surpass 
the values of control cells (data not shown). However, during 
long term incubations, macrophages from tumor-bearing mice were 
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3 
cytotoxic to H-methyl-thymidine-labelled RMB-1 target cells when 
the monoclonal IC5F5 was added. The release of 3H-methyl-
thymidine is comparable to the release of radioactivity of cells 
treated with the lysis agent Triton X-100 (0.1%). When the 
monoclonal antibody 
occur just as in 
was omitted from the assay, 
target cells incubated with 
lysis did not 
Moab alone. 
Macrophages of untreated tumor-bearing and control mice were also 
capable to kill target cells in the presence of Moab, although 
the lysis percentages were lower and varied between 45% and 65%. 
The results of one out of three experiments are presented in 
Figure 2. Macrophages of untreated tumor-bearing animals 
surprisingly had a higher cytolytic activity in the absence of 
Moab than macrophages of treated and control mice. 
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Fig. 2. Lytic activity of peritoneal macrophages as measured by 3H-release, 
72 hours after incubation with methyl-3H-thymidine labelled RMB-1 cells. 
Macrophages were obtained from tumor bearing {10 7 RMB-1 cells i.v.) mice 
treated with Moab IC5F5, tumor bearing non-treated and control mice. Each 
column represents the mean value of ± 1 SEM. 
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~ouocloual_aotibody_tberapy_of tywor-bearing_complewent_deficieot 
D~~l~_wice 
To assess whether CDC plays a major role we have chosen mice 
of the H-2 compatible DBA/2 strain as tumor-recipient. This 
strain is known to be C5 deficient (2). Fifty million of RMB-1 
cells led within 20 days to death of the majority of mice caused 
by disseminated tumor-outgrowth. As shown in Figure 3 animals 
daily treated with 0.2 ml IC5F5 ascites starting 24 hours after 
inoculation of RMB-1 cells showed a considerably prolonged 
survival when compared to control animals (P < 0.02). This 
observation suggests that CDC does not play a major role in 
immunotherapy of DBA/2 mice carrying disseminated RMB-1 tumors. 
About 20% of tumor-bearing mice treated with 4E3 survived till 
60 days after inoculation probably due to histo-incompatibility. 
~onocloP~l -~ntibody toerapy_ip_T~cell_deficieut_wice 
To evaluate the possible role of T cells nude mice were i.v. 
inoculated with 107 RMB-1 cells and treated 3 days later with one 
or repeated daily injections of IC5F5 ascites. BALB/c mice were 
entered in an identical scheme. In 3 repeated experiments the 
treated nude mice showed a significantly prolonged survival as 
compared to non-treated nude mice (P < 0.01), but the length of 
survival (median survival time = 22 days) was considerably less 
than in treated BALB/c mice (median survival time = 31 days, 
(P < 0.003). In addition it should be noted that in all 
experiments a proportion of BALB/c mice survived while all nude 
mice died. The results of one representative experiment are 
shown in Figure 4. These experiments indicate, that therapy with 
specific Moab is effective and that T cells play an auxillary 
role in successful immunotherapy with Moabs. 
Infiltration analysis of_ treated __ and untreated wice 
Mice, which were treated with daily injections of IC5F5 or 
4E3 ascites from the fifth day after i.v. inoculation, were 
killed on day 2, 4, 5, 7 and 9 after start of therapy and organs 
were histologically analysed. In paraffin sections of liver 
tissue of treated mice a striking influx of macrophages was seen 
in liver tumor foci of treated animals from the fourth day after 
onset of therapy (Figure 5a). After 4 days of therapy, differen-
137 
100 
80 
... 
E 60 
0 
> 
~ 
" Cl) 40 
20 
,..~--~"'i--- ---; 
I 
I 
-------. 
I 
I 
------------------------. 
T s 
l l 
I 
I 
-----------, 
I 
'--------//---
----Dolly InJections of IC5F5 I.V. 
-- Dolly InJections of 4E3 I.V. 
T-S Duration of therapy 
L-------------------------------~~ 
~----r-----~----~----~----~----~----~----~-----r~~ 
5 10 15 2a 25 30 35 4a 45 60 
Survival <days> 
Fig. 3. Survival of complement factor C5 deficient DBA/2 inoculated i.v. 
with 5 x 10 7 RMB-1 cells 24 hours before treatment with 0.2 ml IC5F5 ascites 
or 4E3 ascites as control. n = 10 for each group. 
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Fig. 4. Survival of BALB/c and BALB/c nude mice inoculated i.v. with 107 
with RMB-1 cells 72 hours before treatment with one single injection of 
0.2 ml IC5F5 ascites or 4E3 ascites as control. BALB/c: n = 20 for each 
group; BALB/c nude mice: n = 10 for each group. 
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Fig. 5. 
a) RMB-1 tumor in the liver on the fourth day after treatment with 0.2 ml 
IC5F5 ascites; 
b) idem; edema around tumor cells; 
c) idem; macrophages with phagocitized dead RMB-1 cells; 
d) idem; fibroblastic proliferation after tumor destruction. 
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ces in tumor-extension versus destruction between the treated and 
non-treated mice were most evident. In IC5F5 treated mice edema 
was observed between tumor cells (Figure 5b) and phagocytizing 
macrophages were often seen in large areas of destructed tumor 
tissue (Figure 5c). Only bile ducts and some distorted foci of 
hepatocytes were left intact. The lesions showed repair tissue 
with extensive fibroblastic proliferation and deposition of 
collagen (Figure 5d). In 4E3 treated control mice tumor foci 
rapidly increased in size within a few days and scattered 
macrophages were seen in considerable lesser numbers as compared 
to IC5F5 treated mice. Both in treated and in control mice some 
infiltrates contained polymorphonuclear leucocytes, but no major 
influx of lymphocytes could be detected. 
Involvement of T-lymphocytes in treated and untreated tumor-
bearing mice was also investigated by testing cryostate sections 
with the monoclonal antibodies anti-Lyt-1+, anti-L3T4 (helper 
T cell) and anti-Lyt-2+ (cytotoxic/suppressor T .cells). Unfortu-
nately, the common leukocyte antigen marker T200 and common 
T cell marker Thy-1 could not be used because of cross-reactivity 
with the RMB-1 tumor cells (12). Using anti-Lyt-1+ and -Lyt-2+ 
antibodies, only few positive cells were found in tumor foci in 
the livers of control animals. A slightly larger number of 
Lyt-1+ and Lyt-2+ positive cells was sometimes present in IC5F5 
treated BALB/c mice. Lyt-1+ and Lyt-2+ positive cells occurred 
at nearly equal numbers at all timepoints investigated 
(Figure 6a; 6b) and no changes in relative number of Lyt-1+ or 
Lyt-2+ positive cells were observed at the various time intervals 
after start of treatment. 
An increase in number of cells positive for the helper T 
marker L3T4 could not be established in treated mice as compared 
to untreated tumor-bearing mice. It can be concluded from these 
histological observations that in particular macrophages seemed 
to be the effector cells responsible for tumor cell destruction. 
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Fig. 6. Imrnunoperoxidase staining of frozen sections of liver with RMB-1 
tumors 4 days after treatment with IC5F5 ascites: 
a) Incubation with anti-L3T4 
b) incubation with anti-Lyt2+ 
:Q:X:SCTJSSION 
Several alternative mechanisms have been reported, which may 
account for successful sere-immunotherapy. The potential of 
direct in vitro growth inhibition has been attributed to mono-
clonal antibodies, which can block receptor functions. For 
instance, the receptor for the viral envelope protein on lymphoma 
cells could be blocked by an antibody against gp70 preventing 
that gp70 acts as mitogen (34). 
Similarly, both tn vit~o and tn viyQ growth inhibition is 
reported by Masui et al. (33) using Moabs against the epidermal 
growth factor receptor on a carcinoma cell line, and by 
Sauvage et al. (37) using Moabs blocking the transferrin receptor 
of a leukemic cell line. A direct anti-proliferative effect on 
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B cell neoplasms by anti-idiotypic Moabs has been described also 
(31). 
A more subtle approach is the generation of anti-idiotype 
Moabs. Such anti-idiotype antibodies may interact with T cells, 
which express the corresponding idiotype and which are part of 
the putative idiotype network regulating the anti-tumor immune 
response. Modulation of such a network by the use of anti-
idiotype antibodies, may lead to tum6r-destruction by a delayed-
type hypersensitivity reaction (35). 
Until now, immunotherapy models are based on the application 
of Moabs directed against viral antigens on tumors (21,27,38), 
differentiation antigens (3,6,27) or tumor-associated antigens on 
xenografts (18,19). In these cases direct growth inhibition of 
tumor cells by antibody-antigen interaction was not reported, but 
instead the Moabs appeared to mediate cytotoxicity. It is thought 
that tumor-cytotoxicity in most of these models is caused by an 
ADCC, probably mediated by activated macrophages (1,20). This is 
especially true for immunotherapy with antibodies of the IgG2a 
subclass. In our study a Moab of the IgG2a isotype is used which 
evokes an ADCC to RMB-1 tumor cells by macrophages, while in lu 
Yit~9 studies this antibody was also fully capable of CDC in the 
presence of rabbit complement. 
When DBA/2 mice are inoculated with high doses of RMB-1 
cells, which are of BALB/c origin, almost all mice died of 
disseminated tumor. Apparently the minor histocompatibility 
differences between BALB/c and DBA/2 mice are not sufficient to 
prevent tumor cell outgrowth in most mice. As in these C5 
deficient DBA/2 mice immunotherapy was successful, it may be 
concluded that complement dependent cytotoxicity is not a major 
effector mechanism in this model. This is in accordance with 
other studies in AKR mice, which are also C5 deficient (3,29). 
An additional argument against the involvement of CDC is the 
observed delayed tumoricidal effect iU_YiY9 after the injection 
of Moabs. 
Histological studies revealed the abundant presence of 
macrophages as also observed by others during immunotherapy (1) 
or during spontaneous tumor-regression (22). We did not observe 
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extensive phagocytosis of morphologically viable cells, but many 
macrophages were found surrounding or phagocytizing dead cells. 
The long latency phase of about 4 days after therapy, before 
macrophage activation was morphologically at its height point, 
may reflect a slow ADCC mechanism which reaches its maximum after 
48-72 hours (1,20). Our tu_vttro studies confirmed the capabi-
lity of the IgG2a antibody IC5F5 to elicit a slow ADCC to RMB-1 
cells. Strikingly tu_ vitro some lytic activity was seen with 
macrophages attained from untreate9 tumor-bearing mice when no 
antibody in the ADCC test was applied. This phenomenon was not 
present when macrophages were used from treated tumor-bearing 
mice. Macrophages from these latter mice were only capable of 
slow ADCC. Possibly some effector cells of uutreateg tumor-
bearing mice are activated for direct antibody-independent lysis, 
whereas the majority of those of tre~ted mice is mainly primed 
for slow ADCC. These findings correlate well with the results of 
Johnson et al. (20) who proved macrophages to be capable of 
mediating either direct lysis or slow ADCC but not both. 
A diminished immunotherapeutical response of nude mice inocu-
lated with Moloney sarcoma virus transformed cells to i.v. treat-
ment was also found by Kennel et al. (21) and Lamon et al. (27). 
These and our results suggest an additional role of T cells. 
This hypothesis is corroborated by the presence of both 
helper T cells (Lyt-1+ and L3T4+) and supressor/cytotoxic T cells 
(Lyt-2+) cells in infiltrates surrounding tumor cells (Figure 6). 
Cytotoxic Lyt-2+ T cells are able to destruct cells which 
express viral antigens. In retrovirus infected cells such a 
mechanism has repeatedly been reported (16,17,30), but today 
doubt exists if Lyt-2+ cells are the only T cell subset involved 
in cellular mediated cytotoxicity (15,36). Since the action of 
Lyt-2+ cytotoxic T cells is known to be independent of antibodies 
and since histologically only small numbers of Lyt-2+ cells are 
present, it is not probable that cytotoxic T lymphocytes play an 
important role in our model. Moreover, their numbers are hardly 
different from those in untreated mice. Similar observations 
were made in rats with progressing and regressing tumors (32). 
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Evidence for a role of helper T cells in immunotherapy comes 
also from the cellular transfer of IL-2 stimulated helper T 
cells, which are able to induce regression of Friend and Rauscher 
virus induced tumors (7,10). It is likely that sensitized 
helper T cells produce macrophage activating lymphokines which 
promote the influx of macrophages (13,14). This process shows 
similarities to delayed-type hypersensitivity, a type of immune 
response which can indeed be induced by injection of irradiated 
RMB-1 cells in BALB/c mice (25). Therefore we hypothesized that 
in our immunotherapy model T cell mediated influx of macrophages 
around tumor foci may lead to a more effective ADCC and which 
ultimately in some mice may result into complete eradication of 
tumor cells. 
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Delayed-type hypersensitivity (DTH) to Rauscher Murine 
Leukemia Virus (R-MuLV)-encoded or -induced determinants was 
induced in mice by three syngeneic R-MuLV-induced tumor cell 
lines, i.e. a myeloid tumor, RMB-1, an erythroid tumor, RED-1 and 
a lymphoid tumor, RLD-1. 
DTH to subcutaneously (s.c.) administered RMB-1 cells 
appeared on day 4, with a maximum DTH response on day 6 or 7. The 
induction of DTH could be prevented by a tolerizing intravenous 
(i.v.) injection of R-MuLV-induced tumor cells several days 
before the s.c. immunization. 
The three R-MuLV-induced tumor cell lines showed cross 
reactivity in the DTH assay, whereas no cross reactivity was 
found with syngeneic WEHI-3 cells. This indicates that the three 
R-MuLV-induced tumor cell lines share a virally encoded or 
induced antigenic determinant, which activates T cells. 
When the RMB-1 cells used for immunization had been cultured 
in medium supplemented with interferon-~ (IFN-~), the subsequent 
DTH response was increased. This coincided with an increased 
expression of the R-MuLV-specific antigenic determinants on RMB-1 
cells as demonstrated by Scatchard analysis. 
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I~TRODUCTIQ~ 
Immunological tumor-rejection depends on the presence of 
antigenic determinants on the tumor cells, which are not usually 
present on their normal counterparts. Such antigenic determinants 
may be induced by chemical, viral or physical agents and can also 
be found on spontaneously arising tumors (Halliday and Webb, 
1969; Morton et al., 1969; Kripke, 1981; Galetto et al., 1985). 
Cells transformed by RNA tumor viruses express virally encoded 
proteins, and so called virus associated proteins (Nowinski et 
al.,1978; Rogers et al., 1984). These neoantigens can induce 
antibody formation as well 
cellular cytotoxicity and 
(Levy and Leclerc, 1977). 
DTH responses can be 
as cellular immune responses, such as 
delayed-type hypersensitivity (DTH) 
easily elicited to various antigens, 
such as bacteria, viruses, xenogeneic red blood cells, and 
contact sensitizing agents (reviewed by Crowle, 1975). Also tumor 
cells can induce DTH (Halliday and Webb, 1969; Hawrylko, 1980; 
Hoover et al., 1984). DTH reactions are mediated by T cells, 
particularly by the L3T4 positive helper T cell subset (Mossman 
and Coffman, 1987). Evidence is increasing that Lyt-1+2-, L3T4+ 
cells, depending on the experimental conditions, can also mediate 
tumor rejection (Ozawa et al., 1986; Paul et al., 1987; Bookman 
et al., 1987). 
Several adjuvants have been used to increase the anti-tumor 
response, such as BCG (Hawrylko, 1980) and Corynebacterium parvum 
(Dye et al., 1981). One could also increase the anti-tumor 
response by enhancing the immunogenicity of the tumor for 
instance by using haptenated tumor cells (Suda et al., 1986) or 
by treatment with interferon, which is known to increase the 
expression of MHC-coded antigens (Tanaka et al., 1986). 
In previous studies we reported about two R-MuLV-specific 
monoclonal antibodies (MAbs) raised against a R-MuLV-induced 
myeloid tumor (Berends et al., 1988 a-c). One of the MAbs, which 
recognizes virally encoded proteins on RMB-1 cells, was success-
fully used in immunotherapy. A striking difference was found 
between the effect of this MAb therapy in T cell deprived nude 
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mice and their euthymic littermates. This led us to suggest, that 
a T cell dependent anti-tumor immune response is involved. In 
the present study we therefore investigated the ability of BALB/c 
mice to give rise to a DTH response after s.c. immunization with 
R-MuLV-induced tumor cells. 
After having established that R-MuLV-induced tumor cells 
indeed evoke DTH, we investigated the specificity of this 
response, its suppression by a tolerizing 
with irradiated tumor cells and the 
i.v. preimmunization 
effect of interferon-~ 
(IFN-~) on the expression of the R-MuLV-induced tumor cell 
surface antigens and on the immunogenicity of RMB-1 cells as 
measured in the DTH assay. 
~:l.ge 
BALB/c (H-2d) and DBA/2 (H-2d) female mice, four weeks of 
age, were purchased from Bomholtgard, Ry, Denmark. BALB/c (H-2d) 
female mice, four weeks of age, were purchased from HARLAN OLAC 
Ltd, Bicester, U.K. Other BALB/c (H-2d) female and male mice were 
bred at the Dept. of Cell Biology, Immunology and Genetics of the 
Erasmus University. 
C~H_l:l.:o~~ 
Three R-MuLV-induced tumor cell lines were used: a myeloid 
tumor cell line of BALB/c origin (RMB-1), a lymphoid tumor cell 
line of DBA/2 origin (RLD-1), and an erythroid tumor cell line of 
DBA/2 origin (RED-1) (De Both et al., 1978; 1981; 1983; 1985). 
The WEHI-3 immature macrophage cell line of BALB/c origin, 
originally described by Warner et al. (1969), was used as a 
control. This cell line does not express R-MuLV antigens. All 
cell lines were cultured in RPM! 1640 tissue culture medium, 
supplemented with 10% fetal calf serum, glutamin (4 mM), 
penicillin (100 IU/ml), streptomycin (100 ~g/ml) and if necessary 
1 00-150 U IFN- ~ /ml, in a humidified atmosphere with 5% C02. 
IFN-~ was supplied by Drs. M. van Heuvel and I.J. Bosveld as 
culture supernatant from a chinese hamster cell line with the 
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amplified murine recombinant IFN-~ gene (Dijkmans et al., 1985) 
containing 3 x 104 IU/ml. As a control culture supernatant from 
the CH012RO cell line was used (Stefanini et al., 1982). 
~nt~gen_geo~ity_ou_BM~-1 ce~ls 
To quantitate the density of a R-MuLV-encoded surface antigen 
of RMB-1 cells, a Scatchard analysis was performed, using the 
specific MAb IC5F5 that was previously described (Berends et al., 
1988a). Briefly, RMB-1 cells were incubated for 90 minutes at 
room temperature in a volume of 100 ~1 of Hanks' Balanced Salt 
Solution (HBSS), supplemented with 20 mM HEPES and 0.125% gelatin 
containing varying amounts (0.01-10 nM) of 125I-IC5F5. Iodination 
of the MAbs was earlier described (Berends et al. 1988b). For the 
determination of non-specifically bound 125r-IC5F5, the cells 
were incubated with varying amounts of 125I-IC5F5 in the presence 
of excess (10- 6 M) unlabelled IC5F5 for 90 min. Thereafter the 
cells were washed to remove unbound IC5F5. Cell-bound radioacti-
vity was determined in an LKB 1280 ultra-gammacounter. The 
association constant (Ka) and the number of binding sites were 
calculated according to Scatchard (1949). 
Io9uctioo_of_DTH reactivity 
DTH was induced by s.c. immunization of the mice with 3 x 10 7 
irradiated (20 Gy) tumor cells suspended in a volume of 300 ~1. A 
volume of 150 ~1 of this suspension was injected into each 
inguinal area. 
~s~sY for_DT5 
DTH responses were elicited by s.c. injection of 3 to 
6 x 10 6 irradiated (20 Gy) tumor cells, suspended in a volume of 
50 ~1, into the dorsum of the right hind foot seven days after 
the induction of DTH. Unimmunized control mice received this 
challenge only. The difference in thickness of the right and left 
hind foot was measured 24 hours later. The specific DTH response 
was calculated as the relative increase in foot thickness of the 
immunized mice minus the relative increase in foot thickness of 
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the control mice. The increase of foot thickness of the control 
mice ranged between 10 and 20%. 
!nductioo of_sypp~essioo 
Suppression of DTH was induced by i.v. administration of a 
high dose of heavily irradiated (80 Gy) tumor cells, seven days 
prior to the induction of DTH. The administered number of cells 
is indicated in the legends to the figures. 
ll:J::SULTS 
!oductioo of_DTH ~e~ctivity to B-MuLV-ioduceg tumo~ cells 
BALB/c responder mice were s.c. immunized with varying doses 
of syngeneic RMB-1 cells. A maximal DTH response was found after 
s.c. immunization with 3 x 10 7 RMB-1 cells (data not shown). This 
dose was used during all the experiments described. DBA/2 
responder mice were s.c. immunized with 3 x 10 7 syngeneic RED-1 
or RLD-1 tumor cells. Seven days after s.c. immunization all mice 
were challenged with 6 x 10 6 similar tumor cells as used for 
immunization. 
responder strain s.c. immunization challenge o/o specific increase of foot thickness 
BALB/c RMB·1 RMB·1 
DBA/2 RED-1 RED-1 
DBA/2 RLD-1 RLD-1 
0 10 20 30 40 
Fig. 1. DTH reactivity to RMB-1, RED-1 and RLD-1 tumor cells. BALB/c mice 
were s.c. immunized with 3 x 10 7 RMB-1 cells and challenged for DTH with 
6 x 106 RMB-1 cells 7 days later. DBA/2 responder mice were s.c. immunized 
with 3 x 107 RED-1 or RLD-1 cells and challenged for DTH 7 days later with 
6 x 106 RED-1 and RLD-1 cells, respectively. Each column represents the 
mean response ± 1 SEM ( n = 5 l . 
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The RMB-1 cell line induced a pronounced DTH response, whereas 
the responses induced by RED-1 and RLD-1 were weak (Fig. 1). 
~iuetic~ of tbe_DTB re~ponse to_RM~~l cell~ 
Several groups of BALB/c responder mice were s.c. immunized 
with 3 x 107 RMB-1 cells. At various days after immunization, 
individual groups were challenged with 3 x 10 6 RMB-1 cells. From 
day 4 after immunization DTH was detectable with a maximum 
response around day 7 (Fig. 2). 
%specific increase 
of foot thickness 
30 
20 
10 
0 3 4 5 6 7 8 
days after s.c. immunization 
9 
Fig. 2. Kinetics of the DTH response to RMB-1 cells. BALB/c mice were s.c. 
immunized with 3 x 10 7 RMB-1 cells. DTH reactivity was determined at various 
intervals after s. c. immunization. Each experimental point represents the 
mean repsonse± 1 SEM (n = 5). 
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responder strain s.c. immunization challenge % specific increase of foot thickness 
BALB/c RMB·1 RMB-1 1----t 
BALB/c RMB·1 RED-1 1----1 
BALB/c RMB-1 RLD-1 ....... 
BALB/c RMB-1 DBA/2 
BALB/c RMB-1 WEHI-3 1---t 
DBA/2 RED-1 RMB-1 ~ 
DBA/2 RLD-1 RMB-1 H 
DBA/2 RED-1 BALB/c 
DBA/2 RLD-1 BALB/c 
DBA/2 RED-1 RLD-1 I-t 
DBA/2 RLD-1 RED-1 t--t 
0 10 20 30 40 
Fig. 3. Cross-reactivity of tumor associated antigens on RMB-1, RED-1 and 
RLD-1 cells. Several groups of BALB/c mice were s.c. immunized with 3 x 10 7 
RMB-1 cells and challenged for DTH with 6 x 10 6 RMB-1, RED-1 or RLD-1 cells. 
Control mice were challenged with 6 x 10 6 DBA/2 spleen cells or WEHI-3 cells. 
DBA/2 responder mice were s.c. immunized with 3 x 10 7 RED-1 or RLD-1 cells 
and challenged for DTH with 6 x 10 6 cells. A DBA/2 control group was challen-
ged with 6 x 106 BALB/c spleen cells. All cell lines had been cultured with 
IFN-~for the last 24 hours. Each column represents the mean response± 1 SEM 
(n = 5). 
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C~o~~-~e9ctivity_oetweeu_ty~or~9s~oci9ted_antigegs __ ou diffe~eut 
B~~YlV~iuguceg cell_liue~ 
To investigate whether the DTH reactive T cells responding to 
the R-MuLV-induced tumor cell lines recognize a common (presuma-
bly viral) determinant we investigated th~ cross reactivity in 
the DTH assay. Thus, BALB/c mice were s.c. immunized with 3 x 107 
RMB-1 cells and challenged for DTH seven days later with 6 x 10 6 
RMB-1, RED-1 or RLD-1 cells. As a control groups of BALB/c mice 
were challenged with 6 x 106 DBA/2 spleen cells or with WEHI-3 
cells. Fig. 3 shows that after immunization with RMB-1 cells 
challenge with each of the three tumor cell lines led to a 
substantial DTH response (lines 1-3). Challenge with DBA/2 
spleen cells or with the WEHI-3 cell line, however, did not cause 
a DTH response (lines 4 and 5). Cross reactivity between the 
three R-MuLV-induced tumor cell lines was also found after s.c. 
immunization of DBA/2 responder mice with 3 x 107 RED-1 or RLD-1 
cells and challenge with RMB-1 cells (lines 6 and 7), whereas no 
DTH was found after challenge with BALB/c spleen cells (lines 8 
and 9). Cross reactivity was also determined after s.c. immuniza-
tion with RED-1 cells and challenge with RLD-1 cells and vice 
versa (lines 10 and 11). 
Sypp~e~~lQU_Qf_DTH to RMB~j cell~ 
After i.v. injection of BALB/c responder mice with either 
1 x 107 or 5 x 10 7 irradiated RMB-1 tumor cells, s.c. immuniza-
tion with 3 x 10 7 RMB-1 tumor cells did no longer induce a state 
of DTH (Fig. 4). Previous studies have shown that such an i.v. 
preimmunization induced suppressor T (Ts) cells, which can 
suppress the subsequent induction or elicitation of DTH (Van der 
Kwast et al., 1981, Bianchi et al., 1984). This suppression was 
found independent of whether or not the RMB-1 cells had been 
treated with IFN-~ • 
~ffects_gf_!fN-Y_ ou 9Utigeu~e~p~e~~iou_9gg_DTB_~eagtivity 
IFN-~ is known for its enhancing effect on the expression of 
various antigens. We studied the effect of IFN-~ on the express-
ion of R-MuLV-induced antigens. To this end IFN-~ was added to 
the culture medium of RMB-1 cells for 24 or 48 hours. Stimulation 
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responder i.v. preimmunization s.c. immunization treatment of % specific increase of foot thickness 
strain and challenge immunizing cells 
BALB/c 1 X 107RMB-1 RMB-1 control t----1 
BALB/c 5 X 107 RMB-1 RMB-1 control Q----------i 
BALB/c 0.5 ml BSS RMB-1 control !--------1 
BALB/c 1 X 107 RMB-1 RMB-1 24 hours I FN-y ~ 
BALB/c 5 X 107 RMB-1 RMB-1 24 hours I FN-y CJ-----< 
BALB/c 0.5 ml BSS RMB-1 24 hours I FN-y j------1 
0 10 20 30 40 
Fig. 4. Induction of a state of suppression by i.v. administration of 
cells. BALB/c mice were i.v. pre-immunized with either l or 5 x 107 
cells. In one experiment the RMB-1 cells used had been cultured in 
for 24 hours, in the other untreated mice were s.c. immunized with 3 
RMB-1 cells. Another 7 days later the mice were challenged with 6 
RMB-1 cells. Each column represent the mean reponse ± 1 SEM (n = 5). 
RMB-1 
RMB-1 
IFN-)' 
X 107 
X 106 
of RMB-1 cells with IFN-'Y for 24 hours caused a nearly twofold 
increase in the amount of binding sites on RMB-1 cells detected 
by the binding of 125r-labelled-IC5F5 (Fig. 5A), and a slight 
decrease in affinity (Fig. 5B). This coincided with a strong 
enhancement of DTH (Fig. 6). After culture of RMB-1 cells with 
IFN-'Y for 48 hours the increase in R-MuLV antigen-expression was 
much smaller than in RMB-1 cells that had been cultured with 
IFN-'Y for 24 hours. In this case also no enhancing effect in the 
DTH assay was found. Apparently the IFN-'Y -induced increased 
expression of R-MuLV-encoded proteins by RMB-1 cells is only 
temporary. This increased antigen-expression was not due to an 
increase in the cell size (data not shown). 
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Fig. 5. Determination of the number of binding sites and the association 
constant {Ka) of 125I-labelled IC5F5 MAbs on RMB-1 cells by Scatchard analy-
sis. {A) a constant number {4 x 105) of RMB-1 cells was incubated with vary-
ing amounts (0.01-10 nM) of 125r-IC5F5. For the determination of non-specifi-
cally bound 125r-IC5F5, the cells were incubated with excess {lo-6 M) unla-
belled IC5F5 for 90 minutes. B max is the number of binding sites under 
saturated conditions. (B) Ka was calculated by the quotient of 125 I-IC5F5-
bound;l25r-IC5F5-free as compared to the amount of 125r-IC5F5-bound. 
{ 0) untreated RMB-1 cells; B max: 180,000/cell; Ka: 7.4 x 108 1/mol 
{ •) RMB-1 cells cultured with IFN-'Y for 24 hours; B max: 335,000/cell; 
Ka: 4,2 x 108 1/mol 
{A.) RMB-1 cells cultured with IFN-'Y for 48 hours; B max: 218,000/cell; 
Ka: 3,6 x 108 1/mol. 
161 
responder strain s.c. immunization challenge treatment of %specific increase of foot thickness 
immunizing cells 
BALB/c RMB-1 RMB-1 control f-i 
BALB/c RMB-1 RMB-1 24 hours IFN-y i------1 
BALB/c RMB-1 RMB-1 control 1-----i 
BALB/c RMB-1 RMB-1 48 hours I FN-;· 1-----i 
0 10 20 30 40 
Fig_ 6. Effect of IFN-')' on the immunogenicity of RMB-1 cells. BALB/c mice 
were s.c. immunized with 3 x 10 7 RMB-1 cells that had been cultured with 
IFN-')' for 24 or 48 hours. As a control mice were immunized with RMB-1 cells 
that had been cultured in the absence of IFN-')'. Seven days later all mice 
were challenged for DTH with 6 x 106 similar RMB-1 cells. Each column repre-
sents the mean response± 1 SEM (n =5). 
This study shows that R-MuLV-induced tumor cell lines induce 
DTH in syngeneic mice. This T cell dependent response is more 
pronounced in the case of RMB-1 cells, than in the case of RED-1 
and RLD-1 cells. This correlates with the fact that the latter 
two cell lines differ from the RMB-1 cell line in that they are 
virus-producing, whereas RMB-1 is not. Moreover, RMB-1 cells grow 
s.c. only after inoculation of high numbers of cells whereas 
RED-1 and RLD-1 cells do even after s.c. inoculation of low 
numbers (unpublished results). 
The maximum DTH response to RMB-1 cells was found seven days 
after s.c. immunization. This is in accordance with reports by 
others (Hawrylko et al., 1980). DTH responses to histocompatibi-
lity antigens generally peak one or two days earlier. 
All three different R-MuLV-induced cell lines could induce 
DTH although not equally strong. We investigated whether DTH 
induced by s.c. immunization with one cell line could be elicited 
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by challenge with another R-MuLV-induced cell line. Cross reacti-
vity was found in all combinations tested. The response was the 
highest when RMB-1 cells were used for immunization or challenge. 
The cross reactivity between RED-1 and RLD-1 cells was relatively 
weak, as could be expected in view of the weak DTH responses they 
evoke. Together the results suggest that the DTH response is 
directed to a common R-MuLV-encoded or -induced tumor-associated 
antigen, most clearly expressed on RMB-1 cells. 
Even if tumors possess immunogenic determinants they can 
escape elimination by the immune system. The mechanisms involved 
could be the release of suppressive factors by the tumor cells 
(Mizel et al., 1980), or the induction of suppressor cells (for a 
review see North, 1985). Here we report the induction of 
suppression of the subsequent DTH response, by administration of 
a high dose of heavily irradiated tumor cells. Most probably the 
huge amount of tumor antigens leads to the induction of the state 
of suppression. Previously we investigated extensively the 
mechanism of suppression of the DTH response to H-2 and non-H-2 
histocompatibility antigens after i.v. preimmunization, which 
proved to be due to the induction of antigen-specific Ts cells 
(Vander Kwast et al., 1981; Bianchi et al., 1984). Despite of 
this, the possibility should be taken into account that factors 
released by the (irradiated) tumor cells can also give rise to 
the immunosuppression. Particularly the retroviral protein p15E 
should be mentioned in this respect (Bendinelli et al., 1985). 
When suppression can be induced by a huge amount of tumor 
antigens presented to the immune system, this phenomenon might 
play a role in clinical practice, since frequently irradiation is 
used in the therapy of malignant tumors, which leads to massive 
tumor reduction, and therefore to the appearance of large amounts 
of tumor-derived antigens in the bloodstream. This in turn could 
lead to suppression of the induction of an adequate immune 
response. 
One approach to achieve tumor rejection is to prevent or to 
block a possible immunosuppressive mechanism. Alternatively one 
might enhance the hosts' anti-tumor response using adjuvants, 
such as BCG (Hawrylko, 1980) and Corynebacterium parvum (Dye et 
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al., 1981). A third way would be the enhancement of tumor 
immunogenicity. Suda et al. (1986) reported increased anti-tumor 
immunity using haptenated tumor cells. 
Here we show that IFN-~ can temporarily enhance the express-
ion of tumor-specific antigens. Interestingly, in parallel, the 
io_viyo anti-tumor DTH response was enhanced to the same extent 
(Fig. 1). Various authors asked attention for the immunomodula-
tion of interferons (for reviews see Priestman, 1979; Krim, 
1980). Interferons should exert their effects via at least three 
mechanisms e.g. direct cytotoxicity, 
expression on the tumor cells and increased 
increased MHC-antigen 
host-mediated anti-
tumor effects. Most studies on the effect of interferons on tumor 
immunogenicity focus on the increase of the expression of MHC 
antigens on the tumor cells (King and Jones, 1983; Green and 
Phillips, 1986), which would lead to improved recognition by the 
hosts' immune system and subsequently may result in better tumor-
rejection. Accumulation of immature viral budding particles at 
the cell surface due to inhibitory action of IFNat~ has been 
described before (Friedman et al., 1980). The present study 
shows that IFN-~ can also enhance the expression of a virally 
encoded or induced tumor antigen. Greiner et al. (1987) demon-
strated the increased expression of a tumor-associated antigen on 
a human colon-xenograft after treatment with IFN-a. Such 
phenomena are especially of interest when a tumor specific MAb is 
available. Possibly, the effectiveness of MAb therapy of tumors 
can be improved by simultaneous treatment with a tumor antigen-
enhancing lymphokine as IFN-1 • Our results suggest that 
interferons can also be important in the enhancement of the 
cellular anti-tumor immune response. 
We thank Dr. Th.H. van der Kwast for valuable discussion, 
Dr. H. Bril for critically reviewing the manuscript, Mr. J. 
Brandenburg for skilful animal care end Ms. I. de Goey-van Dooren 
and Ms. G. de Korte for excellent secretarial assistance. 
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This thesis deals with the effect of syngeneic monoclonal 
antibodies on tumor elimination. 
The model described in the foregoing chapters consists of a 
Rauscher virus induced myeloid leukemic cell line (RMB-1), the 
cells of which form disseminated foci after intravenous inocula-
tion. Although the leukemia from which the line originates is 
virally induced and the cells express viral proteins, the RMB-1 
cells do not produce virus. 
When inoculated in BALB/c mice an immune response in the host 
is evoked, which makes the generation of monoclonal antibodies 
possible. One of these monoclonal antibodies was selected and 
proved to be directed to g~g-related viral proteins, which are 
consistently expressed on RMB-1 cells (Chapter II). Disseminated 
tumor cells were well accessible for antibodies when this 
monoclonal antibody was injected intravenously (Chapter III). 
Under various conditions successful tumor therapy was 
achieved with ascites fluid containing high titers of this 
monoclonal antibody (Chapter IV). The monoclonal antibody was 
found to be of the IgG2a subclass and is able to mediate both 
complement dependent cytolysis and antibody dependent cellular 
cytotoxicity. Our results favor the latter mechanism being 
potentiated by helper T cells (Chapter V and VI). 
Since the host animals are considered to be fully immuno-
competent, the usefulness of our model is largely determined by 
the properties of the tumor. In comparison with other models 
used for immunotherapy a number of advantages and disadvantages 
of this model will therefore be discussed. 
We consider the following aspects of our model for immunotherapy 
as advantages: 
In_yit~o culture of the RMB-1 tumor offers the possibility to 
screen for antibody reactivity or cytotoxicity. Cultured tumor 
cells can be used at any time to inoculate animals. 
The permanent presence of the target antigen on the tumor 
cells is important to prevent selection of a subpopulation not 
expressing the appropriate antigen and to prevent escape from 
therapy as described by Young and Hakamori (1981) and by Badger 
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and Bernstein (1983). In our model the expression of antigens was 
due to the synthesis of virally encoded proteins. One of these 
proteins, detected by Western blotting techniques, was glycosy-
lated and most probably expressed on the cell membrane. This 
gp50 may be related to g?g glycoproteins expressed on Gross, 
Friend, Moloney and Rauscher virus infected cells (Ledbetter and 
Nowinski, 1977; Evans et al., 1977; Schultz et al., 1979; Edwards 
and Fan, 1980). By immunoperoxidase staining no p30 molecules 
could be detected (unpublished results), although these molecules 
are abundantly present in virus. This finding can be explained by 
assuming that either the proviral gene coding for p30 is deleted 
in RMB-1 cells or the transcripts coding for p30 may not be 
properly processed. 
The antigen density has been related to the effectiveness of 
immunotherapy. Densities correlate positively with successful! 
therapy (Herlyn et al., 1985). High densities ranged from 106 to 
3-4 x 106 molecules per cell, whereas in our case the number of 
binding sites was limited to about 2 x 105 molecules per cell 
which is apparently sufficient for a therapeutic effect. We 
demonstrated, however, a twofold increase after incubation with 
interferon-~ (Chapter VI) which could mean that combination 
therapy may even improve the results so that still higher tumor 
doses can be eradicated. 
Binding of the target antigen by gp50 by IC5F5 monoclonal 
antibody does not affect tumor growth as shown by prolonged 
cocultivation with and without antibodies (Chapter IV). Masui et 
al. (1984), Vollmers et al. (1985) and Sauvage et al. (1987) 
described that inhibition of growth under influence of monoclonal 
antibodies can occur. Although the presence of such a mechanism 
may improve the response to therapy, the role of host effector 
mechanisms in these systems are more difficult to analyse. 
The RMB-1 tumor is immunogenic due to the presence of virally 
induced antigens. Although this may be regarded as a 
disadvantage if the lack of tumor-specific antigens in humans is 
taken into account, immunogenicity may also be an advantage if 
interaction between several mechanisms is studied. As shown in 
Chapter VI, this tumor is able to provoke a DTH reaction and the 
results of our experiments in nude mice (Chapter V) and those of 
others (Kennel et al., 1985; Lamon et al., 1987) stress the 
importance of T cell involvement in virally induced tumors. This 
is apparently less obvious in xenografts on nude mice, which can 
be well treated by monoclonal antibodies (Herlyn and Koprowski, 
1982; Adams et al., 1984). These findings suggest an important 
influence of the tumor cell type on the host. The possible 
interaction between T cells and an ADCC mechanism has been 
discussed already in Chapter V. 
Virus production by the tumor cells is, as already mentioned, 
not detectable (de Both et al., 1981), which is an advantage for 
immunotherapy. 
and may lead 
Circulating virus particles may block antibodies 
to 
especially when the 
the continuous infection of new target cells, 
antibodies do not neutralize the virus. 
Moreover the viral particles are able to induce immunosuppression 
along different ways (rev. Bendinelli et al., 1985). 
We have used disseminated tumor foci in our studies, since 
sero-immunotherapy may be especially useful for treatment of 
small quantities of residual tumor cells. This situation repre-
sents better the clinical situation, in which problems are often 
caused particularly by the presence of residual, disseminated 
tumor. Small foci can be managed more readily by immune effector 
mechanisms than large tumors and are in general well accessible 
for antibodies and effector cells (Chapter III and V). Large 
(subcutaneous) tumors, however, may lead to local effector cell 
deficiencies (Johnson et al., 1979), and may therefore better be 
treated by conventional therapy. 
Tbe_followtQg_tte~~-~ay_~e_con~tge~eg_as _dt~adv?Qt?ge~ __ Qf_ tht~ 
mogel~ 
It is clear that this model has a number of limitations. The 
potential value of our experimental results for human tumor 
treatment remains difficult to predict. Although adult human 
T cell leukemia is known to be caused by HTLV-1 and cervix or 
hepatocellular carcinoma is frequently associated with certain 
virus strains (Zur Hausen, 1980), most human cancers have no 
proven viral etiology. The obvious consequence is that a number 
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of interactions present in this model, may play only a minor role 
in the treatment of human malignancies. 
Tumors composed of leukemic cells may differ in biological 
behaviour to carcinomas which are the majority of human malig-
nancies. The differences may be dependent on the preservation of 
certain functions of the cell type from which these tumors are 
derived and may for instance become manifest by the degree of 
stroma reaction, necrosis or cohaesiveness which they provoke. 
Theoretically such factors may have implications for therapy, 
since the local situation influences antibody and effector cell 
penetration. Another drawback of the use of leukemic cells as 
tumor model is sometimes the difficulty to discern the neoplastic 
cells from host effector cells, particularly in immunohistologi-
cal analyses (Delwel et al., 1987). 
Spontaneous metastases lead to a particular distribution 
pattern of tumor cells in the host, which is dependent also on 
acquired properties of the tumor cells, and may be absent in 
their parental tumors. These factors may affect immunotherapy of 
metastases. The consequences of these factors can not be studied 
in our model since therapy concerns the elimination of 
multicentric outgrowth of RMB-1 tumor cells which appear not 
mutually different. 
In a number of tumors the vascularisation is increased by 
tumor-derived angiogenic factors. Subcutaneous RMB-1 tumors lack 
extensive vascularisation and show readily central necrosis. Poor 
vascularization may hamper penetration of effector cells and 
antibodies. Therefore in our model subcutaneous tumors would be 
less suitable for immunotherapy studies. In our immunotherapy 
experiments this factor is circumvented by the treatment of small 
disseminated tumor foci. 
If inoculated properly the RMB-1 tumor grows rapidly and kills 
the host within a short time. This rapid growth is of benefit in 
therapy studies by giving quick results. On the other hand, 
however, the critical, therapy-refractory period is soon reached 
and may counteract a fine tuning of the dose response regimens. 
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Our studies lead to the followong conclusions with regard to 
immunotherapy with monoclonal antibodies in the model employed iu 
tbis_tbesi~: 
1) The Rauscher virus induced myeloid cell line is able to 
elicit an immune response in the syngeneic host. This allows 
the immortalization of syngeneic antibody producing cells by 
the hybridoma technology. 
2) RMB-1 cells express virally encoded antigens on the cell 
surface, which could be used as tumor-specific antigens in an 
immunotherapy model. 
3) Interferon-~ increases the number of monoclonal antibody 
binding sites, and may be therefore, apart from other 
aspects, useful for combination therapy. 
4) Radioactive-labelled specific monoclonal antibodies bind 
preferentially to targets in_vivQ. Binding is particularly 
prominent in well-vascularized parts of the tumor. 
5) Successful immunotherapy with specific monoclonal antibodies 
is possible in the immunocompetent host provided the tumor 
burden is smaller than ~ 2-3 x 10 8 cells which is about 1% of 
body weight. 
6) Initial high doses of antibody are required for successful 
therapy. 
7) No detectable modulation of the target antigen occurs during 
therapy. 
8) The presence of the complement factor C5 is not a prerequi-
site for successful immunotherapy. 
9) ADCC plays an important role in the tumor destruction and is 
probably particularly mediated by macrophages. 
10) Tumor destruction is T cell dependent possibly via a DTH res-
ponse acting in an additive or a synergistic way with ADCC. 
The latter item (10) needs some comment: 
Phagocytosis of RMB-1 tumor cells may yield antigen presenting 
cells which are able to activate helper T cells. The helper 
T cells in turn may stimulate macrophages for direct killing of 
tumor cells. This (DTH) mechanism may coexist with ADCC, causing 
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both separately the elimination of tumor cells. A complex inter-
action of both mechanisms, however, is imaginable as well. 
According to this view the helper T cells may also activate 
macrophages for ADCC which further intensifies this mechanism. 
Some of these involved macrophages again may function as antigen 
presenting cells and may recruit new helper T cells. In this way 
the DTH reactivity will be amplified. 
(For references: see Introduction) 
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The treatment of disseminated cancer is still a matter of 
radiotherapeutical and chemotherapeutical intervention. These 
modalities have their drawbacks by exerting detrimental effects 
on the host. The investigations on a more selective therapy based 
on the immune reactions against tumor cells may therefore be 
advantageous. 
This thesis deals with the treatment of disseminated tumors 
with specific monoclonal antibodies. 
In an experimental model we have used a Rauscher virus 
induced, non-producing murine myeloid cell line derived from 
BALB/c mice (RMB-1). This cell line carries tumor-restricted 
antigens, which are immunogenic in the syngeneic host. The 
generation and characterization of two specific monoclonal 
antibodies of respectively the IgG2a and IgG2b subclass are 
reported in Chapter II. These monoclonal antibodies are directed 
to virally encoded g?g-related proteins, expressed on the 
transformed myeloid cells. This is established by Western blot 
analysis of virus and RMB-1 lysates whereas the tissue 
specificity is determined by immunoperoxidase studies on fetal 
and adult BALB/c tissues and the ultrastructural localization by 
immune-electron microscopy. No cross-reactivity with normal 
tissues was seen. 
The accessibility of radioactive-labelled monoclonal antibo-
dies to disseminated tumors is proved in Chapter III by total 
body scanning and by autoradiography. 
Since antibody clearance may be important to establish dose 
regimens in immunotherapeutical studies, these parameters were 
also measured in tumor-bearing and control mice and show a 
decrease of the initial serum radioactivity of about 50% and 90% 
in 24 hours for respectively IC5F5 and 4D2B4. 
In Chapter IV the effects of syngeneic monoclonal antibody 
therapy on established disseminated tumors was investigated by 
the use of the IgG2a monoclonal antibody IC5F5. From survival 
curves of treated and control tumor-bearing mice substantial 
evidence is obtained for effective therapy if treatment is 
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started within 5 days after intravenous inoculation of tumor 
cells. Untreated mice died within 15-20 days. An initial high 
dose of monoclonal antibodies seems most relevant. 
In Chapter V the underlying mechanisms were explored by means 
of immunotherapeutical studies in complement factor C5 deficient 
DBA/2 mice and T cell deficient BALB/c nude mice. These studies 
were accompanied by (immuno)histochemical analysis of the tumor 
infiltrates in treated and non-treated tumor-bearing BALB/c mice 
and by in vitro studies on complement dependent (CDC) and 
antibody mediated cellular cytotoxicity (ADCC). This study 
suggested the presence of ADCC, most likely mediated by 
macrophages, whereas a major role of complement dependent 
cytolysis appeared to be unlikely. 
In Chapter VI additional studies are reported on a delayed-
type hypersensitivity (DTH) elicited by the tumor using the foot 
swelling assay. The conclusions from these latter two studies 
(Chapter V and VI) indicated an important role for T cells in 
this model. 
It is hypothesized that in our model a DTH reaction on the 
tumor causes a helper T cell mediated influx of macrophages 
around tumor foci which may lead to a more effective ADCC, 
resulting in a complete eradication of tumor cells. However, 
elimination of tumor cells by both mechanisms individually is not 
excluded. Future studies should delineate the relative 
contribution of both types of immune elimination of tumor cells, 
and whether these responses operate additively or 
synergistically. 
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Voor de behandeling van gemetastaseerde tumoren wordt nog 
steeds gebruik gemaakt van radio- en chemotherapie. Deze behande-
lingsmethoden hebben echter nadelen door hun ernstige 
bijwerkingen. Onderzoek naar een meer selectieve behandelingsvorm 
gebaseerd op immuunreactiviteit gericht tegen tumoren kan hierin 
mogelijk verbetering brengen. 
Dit proefschrift behandelt immunotherapie van muizen met 
metastasen m.b.v. specifieke monoclonale antilichamen. In een 
proefdier model is gebruik gemaakt van een door het Rauscher 
leukemie virus in BALB/c muizen geinduceerde myeloide cellijn 
(RMB-1) welke geen virus produceert. Deze cellijn draagt tumor-
specifieke antigenen welke immunogeen zijn in de BALB/c muizen. 
De selectie en karakterisering van twee specifieke monoclonale 
antilichamen van respectievelijk de IgG2a en IgG2b subklasse wordt 
vermeld in Hoofdstuk II. Deze monoclonale antilichamen zijn 
gericht tegen viraal gecodeerde, g~g-geassocieerde eiwitten, 
aanwezig op de getransformeerde myeloide cellen. Dit is vastge-
steld door middel van Western blot analyse van virus en RMB-1 
lysaten, terwijl de weefselspecificiteit is bepaald met behulp van 
immunoperoxidase studies op foetaal en volwassen BALB/c weefsels 
en de ultrastructurele localisatie door middel van immune-
electron microscopie. 
De bereikbaarheid van de tumoren voor de radioactief gemerkte 
monoclonale antilichamen is aangetoond met behulp van 'total body 
scanning' en autoradiografie (Hoofdstuk III). Daar de klaring van 
antilichamen van belang kan zijn voor het bepalen van dosering 
schema's in immunotherapeutische studies, werden deze parameters 
eveneens gemeten in tumor dragende en controle muizen. De gemeten 
waarden tonen een daling van de initi~le serum radioactiviteit 
van ongeveer 50% en 90% voor respectievelijk IC5F5 en 4D2B4 in 
24 uur. In hoofdstuk IV werd de therapeutische werking onderzocht 
van syngene monoclonale antilichamen op gedissemineerde tumoren, 
gebruik makend van het monoclonale antilichaam IC5F5. 
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Uit overlevingscurves van behandelde en controle tumor-
dragende muizen bleek een duidelijk therapeutisch effect indien de 
behandeling werd gestart binnen 5 dagen na intraveneuze tumor 
inoculatie. Een hoge aanvangsdosis lijkt vooral van belang. 
Onbehandelde muizen overleden na een tijdsduur van 15-20 dagen. 
In hoofdstuk V werden de werkingsmechanismen onderzocht door 
middel van immunotherapeutische studies in C5 deficiente DBA/2 
muizen en T eel deficiente BALB/c naakte muizen. Tevens werden 
(immuno)histochemische analyses van tumor infiltraten in tumor-
dragende behandelde en onbehandelde BALB/c muizen verricht. 
Hiernaast werden in vitro studies met betrekking tot complement 
afhankelijke (CDC) en antilichaam afhankelijke cellulaire cytoto-
xiciteit (ADCC) uitgevoerd. 
Deze studie maakte bet belang van een antilichaam afhankelijke 
cellulaire cytotoxiciteit door middel van macrofagen aannemelijk, 
terwijl een belangrijke rol van complement afhankelijke cytolysis 
minder waarschijnlijk werd. 
In hoofdstuk VI worden studies beschreven ten aanzien van de 
door de tumor geinduceerde vertraagd-type overgevoeligheidsreac-
tie (DTH). Hiertoe werd gebruik gemaakt van een assay waarbij 
zwelling van de achterpoot wordt gemeten als gevolg van de 
immuun-respons na locale injectie van tumorcellen volgend op s.c. 
immunisatie. 
De conclusie uit beide laatste studies suggereren een belang-
rijke rol van T cellen in dit model gedurende de therapie met 
monoclonale antilichamen. 
Als hypothese wordt gedacht aan een door de tumor opgeroepen 
DTH reactie, waarbij via geactiveerde T helper cellen een influx 
van macrofagen rond de tumor ontstaat. Dit kan leiden tot een 
meer effectieve ADCC met totale eliminatie van tumor cellen. 
Vernietiging van tumor 
afzonderlijk kan echter 
cellen via 
niet worden 
beide werkings mechanismen 
uitgesloten. Toekomstige 
studies zullen bet aandeel van beide mechanismen moeten afgrenzen 
en een synergistische of additieve werking van belden moeten 
aantonen. 
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afdeling Immunologie die zonder aarzelen medewerking verleenden 
en mijn taak in dit deel van het onderzoek overnamen toen de tijd 
hiervoor mij verder ontbrak. Hen ben ik zeer erkentelijk, alsmede 
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Prof.Dr. R. Benner die m~ ook de gelegenheid gaf m~n werk naar 
buiten te presenteren. Van de afdeling Immunologie en Celbiologie 
ben ik ook dank verschuldigd aan Drs. N.A. Bos, Dr. W. van Ew~k 
en Drs. P.J.M. Leenen en medewerkers voor hun vaak zeer spontane 
hulp. 
De inzet van Mevr. M. Hanegraaff die het volledige typewerk 
en de lay-out op prettige w~ze voor haar rekening heeft genomen, 
heb ik zeer gewaardeerd. Ook dank ik Mevr. P.C. Delfos voor haar 
hulp en het verzorgen van het hoog gekwalificeerde fotomateriaal. 
Prof.Dr. A. Dekker van de afdeling Pathologie van het Presby-
terian Hospital te Pittsburg, die 1 jaar als gast-hoogleraar aan 
onze afdeling verbonden was, dank ik voor z~n bereidheid de 
eerste 3 artikelen op de engelse taal te hebben willen 
corrigeren. 
Tot slot wil ik ook de leden van de promotiekommissie, te 
weten Prof.Dr. J. Abels, Prof.Dr. R. Benner, Prof.Dr. J. Jeekel 
en mijn promotor Prof.Dr. R.O. van der Heul, danken voor hun 
bereidwilligheid zich te verdiepen in het manuscript en m~ te 
voorzien van correcties en waardevolle suggesties. 
Bovenal echter wil ik m~n vrouw danken, die na 7 zeer 
onrustige en onzekere jaren, nogmaals 5 jaar veel van m~n taken 
in het gezin op zich nam, teneinde dit werk mogel~k te maken. 
Cu~~ic~lum_vit?e 
De auteur werd in 1950 geboren te Dordrecht. Na het behalen 
van het HBS-B diploma werd in 1968 begonnen met de studie genees-
kunde te Utrecht, welke werd beeindigd in 1975. Aansluitend was 
de schrijver voor 1 jaar verbonden aan de afdelingen Chirurgie 
(Drs. P.G. Oe, Dr. H.M. Kluck en Drs. J.T. Tantua) en Gynaecolo-
gie/Verloskunde (Drs. P.J.A.M. Wijffels en Drs. W.L.A. Stroobands) 
van het St. Jozef Ziekenhuis te Kerkrade. Na afronding van de 
nationale tropencursus volgde vanaf 1977 een periode van 3 jaar 
waarin de auteur, via uitzending door Memisa, 
was aan het Hopital St. Jean de Dieu te Boko 
Populaire du Benin. Na terugkomst werd, na 9 
als arts verbonden 
in de Republique 
maanden als arts-
assistent werkzaam te zijn geweest op de chirurgische afdeling van 
het Marien Hospital te Kevelaer in West-Duitsland (Dr. W. Schwa-
nitz), in 1981 begonnen met de opleiding tot anaesthesist op de 
afdeling Anaesthesiologie van het Academisch Ziekenhuis te Leiden 
(hoofd Prof.Dr. J. Spierdijk). Deze opleiding werd echter na 
1 jaar verwisseld voor de opleiding huisartsgeneeskunde aan het 
Universitair Huisartsen Instituut te Utrecht (toenmalig tijdelijk 
hoofd Dr. K. Gill). Na afronding hiervan was de schrijver werkzaam 
op de afdeling Klinische Pathologie van het Academisch Ziekenhuis 
Rotterdam-Dijkzigt (hoofd Prof.Dr. R.O. van der Heul) als arts-
assistent in opleiding. Tijdens deze periode werd het in dit 
proefschrift beschreven onderzoek verricht. Vanaf 1 juli 1988 is 
de schrijver verbonden als patholoog-anatoom aan het Pathologisch-
Anatomisch Laboratorium voor Dordrecht en Omstreken. 
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ADCC 
BCG 
BSA 
CDC 
CEA 
CTL 
DNA 
DTH 
ELISA 
env 
FACS 
FCS 
FITC 
FMR 
gag 
gp 
Gy 
HBSS 
HIV 
HTLV 
IF 
IFN 
Ig 
IL 
i.p. 
i.v. 
Ka 
L .I. 
LTR 
- antibody dependent cellular cytotoxicity 
- Bacillus Calmette - Gu~rin 
- bovine serum albumin 
- complement dependent cytotoxicity 
- carcino embryonic antigen 
- cytotoxic T lymphocyte 
- deoxyribonucleic acid 
- delayed-type hypersensitivity 
- enzyme-linked immunosorbent assay 
- envelope (gene coding for envelope proteins) 
- fluorescence activated cell sorter 
- fetal calf serum 
- fluorescein isothiocyanate 
- Friend/Moloney/Rauscher 
- group specific antigens (gene coding for core protein) 
- glycoprotein 
- Gray 
- Hanks' balanced salt solution 
- human immunodeficiency virus 
human T-cell leukemia virus 
- immunofluorescence 
- interferon 
- immunoglobulin(s) 
- interleukin 
- intraperitoneally 
intravenously 
- association constant 
- labeling index 
- long terminal repeat 
Mab/Moab- monoclonal antibody 
MCF 
MHC 
MLTC 
MST 
MSV 
- Mink cell focus-inducing 
- major histocompatibility complex 
- mixed lymphocyte tumor culture 
- median survival time 
Moloney sarcoma virus 
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MuLV 
NK 
n.t. 
p 
PBS 
pol 
Murine leukemia virus 
- natural killer 
- not tested 
- protein 
- phosphate buffered saline 
- RNA-dependent DNA polymerase (gene coding for reverse 
transcriptase) 
Pr - precursor protein 
RED - Rauscher virus induced erythroid cell line of DBA/2 
origin 
RIA - radio-immuno assay(s) 
RLD - Rauscher virus induced lymphoid cell line of DBA/2 
origin 
RMB - Rauscher virus induced myeloid cell line of Balb/c 
RNA 
s.c. 
SEM 
SFFV 
Ts 
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origin 
- ribonucleic acid 
- subcutaneously 
- standard error of the mean 
- spleen focus forming virus 
- suppressor T 
